A family of proteins, including a specific human protein designated as HIP1, has been identified that interact differently with the gene product of a normal (16 CAG repeat) and an expanded (>44 CAG repeat) HD gene. Expression of the HIP1 protein was found to be enriched in the brain. Analysis of the sequence of the HIP1 protein indicated that it includes a death effector domain (DED), suggesting an apoptotic function. Thus, it appears that a normal function of Huntingtin may be to bind HIP1 and related apoptosis modulators, reducing its effectiveness in stimulating cell death. Since expanded huntingtin performs this function less well, there is an increase in HIP1–modulated cell death in individuals with an expanded repeat in the HD gene. This understanding of the likely role of huntingtin and HIP1 or related proteins (collectively "HIP–apoaposis modulating proteins") in the pathology of Huntington’s disease offers several possibilities for therapy. First, because the function of huntingtin apparently depends at least in part on the ability to interact with HIP–apoaposis modulating proteins, added expression (e.g., via gene therapy) of normal (non-expanded) huntingtin or of the HIP–binding region of huntingtin should provide a therapeutic benefit. Other DED–interacting peptides could also be used to mask and reduce the interaction of HIP–apoaposis modulating proteins with the death signaling complex. Alternatively, a mutant form of HIP–protein from which the DED has been deleted might be introduced, for example using gene therapy techniques. Because HIP–apoaposis modulating proteins have been shown to self–associate, a protein with a deleted DED may compete with endogenous HIP–protein in the formation of these associations, thereby reducing the amount of apoptotically–active HIP–protein.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>AL</th>
<th>Albania</th>
<th>ES</th>
<th>Spain</th>
<th>LS</th>
<th>Lesotho</th>
</tr>
</thead>
<tbody>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslavia</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KP</td>
<td>Democratic People's</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SR</td>
<td>Sweden</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td>SK</td>
<td>Slovakia</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td>TD</td>
<td>Chad</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>TJ</td>
<td>Tajikistan</td>
<td>TM</td>
<td>Turkmenistan</td>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>TT</td>
<td>Trinidad and Tobago</td>
<td>UA</td>
<td>Ukraine</td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td>UX</td>
<td>Uzbekistan</td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>YU</td>
<td>Yugoslavia</td>
<td>ZW</td>
<td>Zimbabwe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
APOPTOSIS MODULATORS THAT INTERACT WITH THE HUNTINGTON’S DISEASE GENE

BACKGROUND OF THE INVENTION

This application relates to a family of apoptosis modulators that interact with the Huntington's Disease gene product, and to methods and compositions relating thereto.

"Interacting proteins" are proteins which associate in vivo to form specific complexes. Non-covalent bonds, including hydrogen bonds, hydrophobic interactions and other molecular associations form between the proteins when two protein surfaces are matched or have affinity for each other. This affinity or match is required for the recognition of the two proteins, and the formation of an interaction. Protein-protein interactions are involved in the assembly of enzyme subunits; in antigen-antibody reactions; in forming the supramolecular structures of ribosomes, filaments, and viruses; in transport; and in the interaction of receptors on a cell with growth factors and hormones.

Huntington's disease is an adult onset disorder characterized by selective neuronal loss in discrete regions of the brain and spinal chord that lead to progressive movement disorder, personality change and intellectual decline. From onset, which generally occurs around age 40, the disease progresses with worsening symptoms, ending in death approximately 18 years after onset.

The biochemical cause of Huntington's disease is unclear. While the biochemical cause of Huntington's disease has remained elusive, a mutation in a gene within chromosome 4p16.3 subband has been identified and linked to the disease. This gene, referred to as the Huntington's Disease or HD gene, contains two repeat regions, a CAG repeat region and a CCG repeat region. Testing of Huntington's disease patients has shown that the CAG region is highly polymorphic, and that the number of CAG repeat units in the CAG repeat region is a very reliable indicator of having inherited the gene for Huntington's disease. Thus, in control individuals and in most individuals suffering from neuropsychiatric disorders other than Huntington's disease, the number of CAG repeats is between 9 and 35, while in individuals suffering from Huntington's disease the number of CAG repeats is expanded and is 36 or greater.
To date, no differences have been observed at either the total RNA, mRNA or protein levels between normal and HD-affected individuals. Thus, the function of the HD protein and its role in the pathogenesis of Huntington's Disease remain to be elucidated.

**SUMMARY OF THE INVENTION**

We have now identified a protein designated as HIP1, that interact differently with the gene product of a normal (16 CAG repeat) and an expanded (>44 CAG repeat) HD gene. The HIP1 protein originally isolated from a yeast two-hybrid screen is encoded by a 1.2 kb cDNA (Seq. ID. No. 1), devoid of stop codons, that is expressed as a 400 amino acid polypeptide (Seq. ID. No. 2). Subsequent study has elucidated additional sequence for HIP1 such that a 1090 amino acid protein is now known. (Seq. ID No. 5). Expression of the HIP1 protein was found to be enriched in the brain.

Analysis of the sequence of the HIP1 protein indicated that it includes a death effector domain (DED), suggesting an apoptotic function. Thus, it appears that a normal function of huntingtin may be to bind HIP1 and related apoptosis modulators, reducing its effectiveness in stimulating cell death. Since expanded huntingtin performs this function less well, there is an increase in HIP1-modulated cell death in individuals with an expanded repeat in the HD gene. Furthermore, additional members of the same family of proteins have been identified which also contain a DED. Thus, the present invention provides a new class of apoptotic modulators which are referred to as HIP-apoptosis modulating proteins.

This understanding of the likely role of huntingtin and HIP1 or related proteins in the pathology of Huntington’s Disease offers several possibilities for therapy. First, because the function of huntingtin apparently depends at least in part on the ability to interact with HIP-apoptosis modulating proteins, added expression (e.g., via gene therapy) of normal (non-expanded) huntingtin or of the HIP-binding region of huntingtin should provide a therapeutic benefit. Other DED-interacting peptides could also be used to mask and reduce the interaction of HIP-apoptosis modulating proteins with the death signaling complex. Alternatively, a mutant form of HIP-protein from which the DED has been deleted might be introduced, for example using gene therapy techniques. Because HIP-apoptosis modulating proteins have been shown to self-associate, a protein with a deleted DED may compete with
endogenous HIP-protein in the formation of these associations, thereby reducing the amount of apoptotically-active HIP-protein.

**BRIEF DESCRIPTION OF THE DRAWING**

Fig. 1 graphically depicts the amount of interaction between HIP1 and Huntingtin proteins with varying lengths of polyglutamine repeat;

Fig. 2 compares the nucleic acid sequences of human and murine HIP1 and HIP1a;

Fig. 3 compares the amino acid sequences of human and murine HIP1 and HIP1a;

Fig. 4 shows the sequences of various death effector domains in comparison to the DED of human and murine HIP1 and HIP1a;

Fig. 5 shows the genomic organization of human HIP1;

Fig. 6 compares the sequences of human HIP1 with ZK370.3 protein of *C. elegans*;

Fig. 7 shows mouse EST’s with homology to human HIP1 cDNA used to screen a mouse brain library;

Fig. 8 shows the affect of HIP1 on susceptibility of cells to stress; and

Figs. 9A - 9C show the toxicity of HIP1 in the presence of huntingtin with different lengths of polyglutamine repeats.

**DETAILED DESCRIPTION OF THE INVENTION**

This application relates to a new family of proteins function as modulators of apoptosis. At least some of these proteins, notably the human protein designated HIP1, interact with the gene product of the Huntington’s disease gene. Other proteins within the family possess at least 40% and preferably more than 50% nucleotide identity with HIP1 and include a death effector domain (DED). This proteins are referred to in the specification and claims hereof as "HIP-apoptosis modulating proteins."

The first HIP-apoptosis modulating protein identified was designated as HIP1. HIP1 was identified using the yeast two-hybrid system described in US Patent No. 5,283,173 which is incorporated herein by reference. Briefly, this system utilizes two chimeric genes or plasmids expressible in a yeast host. The yeast host is selected to contain a detectable marker gene having a binding site for the DNA binding domain of a transcriptional activator. The
first chimeric gene or plasmid encodes a DNA-binding domain which recognizes the binding site of the selectable marker gene and a test protein or protein fragment. The second chimeric gene or plasmid encodes for a second test protein and a transcriptional activation domain. The two chimeric genes or plasmids are introduced into the host cell and expressed, and the cells are cultivated. Expression of the detectable marker gene only occurs when the gene product of the first chimeric gene or plasmid binds to the DNA binding domain of the detectable marker gene, and a transcriptional activation domain is brought into sufficient proximity to the DNA-binding domain, an occurrence which is facilitated by protein-protein interactions between the first and second test proteins. By selecting for cells expressing the detectable marker gene, those cells which contain chimeric genes or plasmids for interacting proteins can be identified, and the gene can be recovered and identified.

In testing for Huntington Interacting Proteins, several different plasmids were prepared containing portions of the human HD gene. The first four, identified as 16pGBT9, 44pGBT9, 80pGBT9 and 128pGBT9, were GAL4 DNA binding domain-HD in-frame fusions containing nucleotides 314 to 1955 (amino acids 1-540) of the published HD cDNA sequences cloned into the vector pGBT9 (Clontech). These plasmids contain a CAG repeat region of 16, 44, 80 and 128 glutamine-encoding repeats, respectively. A clone (DMK BamHIpGBT9) was made by fusing a cDNA encoding the first 544 amino acids of the myotonic dystrophy gene (a gift from R. Korneluk) in-frame with the GAL4-DNA BD of pGBT9 and was used as a negative control.

These plasmids have been used to identify and characterize HIP1, as well as two additional HD-interacting proteins, HIP2 and HIP3, which have not yet been tested for function as apoptosis modulators. These plasmids can be further used for the identification of additional interacting proteins which do act as apoptosis modulators, and for tests to refine the region on the protein in which the interaction occurs. Thus, one aspect of the invention is these four plasmids, and the use of these plasmids in identifying HD-interacting proteins. Furthermore, it will be appreciated that the GAL4 DNA-binding and activating domains are not the only domains which can be used in the yeast two-hybrid assay. Thus, in a broader sense, the invention encompasses any chimeric genes or plasmids containing nucleotides 314 to 1955 of the HD gene together with an activating or DNA-binding domain suitable for use
in the yeast one, two- or three-hybrid assay for proteins critical in either binding to the HD protein or responsible for regulated expression of the HD gene.

After introducing the plasmids into Y190 yeast host cells, transforming the host cells with an adult human brain Matchmaker™ (Clontech) cDNA library coupled with a GAL4 activating domain, and selecting for the expression of two detectable marker genes to identify clones containing genes for interacting proteins, the activating domain plasmids were recovered and analyzed. As a result of this analysis, three different cDNA fragments were identified as encoding for HD-interacting proteins and designated as HIP1, HIP2 and HIP3. The nucleic acid sequence of HIP1, as originally recovered in the yeast two-hybrid assay, is given in Seq. ID. No 1. The polypeptide which it encodes is given by Seq. ID No. 2. Further investigation of the HIP1 cDNA resulted in the characterization of a longer region of cDNA totaling 4795 bases and a corresponding protein, the sequences of which are given by Seq ID Nos. 3 and 4, respectively. A further portion of the HIP1 protein was characterized, extending the length to the complete protein sequence of 1090 amino acids (Seq. ID No. 5)

The cDNA molecules encoding HIP-apoptosis modulating proteins, particularly those encoding portions of HIP1, can be explored using oligonucleotide probes for example for amplification and sequencing. In addition, oligonucleotide probes complementary to the cDNA can be used as diagnostic probes to localize and quantify the presence of HIP1 DNA. Probes of this type with a one or two base mismatch can also be used in site-directed mutagenesis to introduce variations into the HIP1 sequence which may increase or decrease the apoptotic activity. Preferred targets for such mutations would be the death effector domains. Thus, a further aspect of the present invention is an oligonucleotide probe, preferably having a length of from 15-40 bases which specifically and selectively hybridizes with the cDNA given by Seq. ID No. 1 or 3 or a sequence complementary thereto. As used herein, the phrase "specifically and selectively hybridizes with" the cDNA refers to primers which will hybridize with the cDNA under stringent hybridization conditions.

Probes of this type can also be used for diagnostic purposes to characterize risk of Huntington’s Disease like symptoms arising in individuals where the symptoms are present in the family history but are not associated with an expansion of the CAG repeat. Such symptoms may arise from a mutation in HIP1 or other HIP-apoptosis modulating protein
which alters the interaction of this protein with huntingtin, thereby increasing the apoptotic activity of the protein even in the presence of a normal (non-expanded) huntingtin molecule. An appropriate probe for this purpose would one which hybridizes with or adjacent to the huntingtin binding region of the HIP-apoptosis modulating protein. In HIP1, this lies within amino acids 129-514.

DNA sequencing of the HIP1 cDNA initially isolated from the yeast two-hybrid screen (Seq. ID No. 1) revealed a 1.2 kb cDNA that shows no significant degree of nucleic acid identity with any stretch of DNA using the blastn program at ncbi (blast@ncbi.nlm.nih.gov). When the larger HIP1 cDNA sequence (SEQ ID NO. 3) was translated into a polypeptide, the HIP1 cDNA coding (nucleotides 328-3069) is observed to be devoid of stop codons, and to produce a 914 amino acid polypeptide. A polypeptide identity search revealed an identity match over the entire length of the protein (46% conservation) with that of a hypothetical protein from \textit{C. elegans} (ZK370.3 protein; \textit{C. elegans} cosmid ZK370). This \textit{C. elegans} protein shares identity with the mouse talin gene, which encodes a 217 kDa protein implicated with maintaining integrity of the cytoskeleton. It also shares identity with the SLA2/MOP2/END4 gene from \textit{Saccharomyces cerevisiae}, which is known to code for an essential cytoskeletal associated gene required for the accumulation and or maintenance of plasma membrane H⁺ ATPase on the cell surface.

When pairwise comparisons are performed between HIP1 and the \textit{C. elegans} ZK370.3 protein (Genpept accession number celzk370.3), it shows 26% complete identity and an overall 46% level of conservation. Comparative analysis between HIP1 and SLA2/MOP2/END4 (EMBL accession number Z22811) demonstrate similar conservation (20% identity, 40% conservation).

Further exploration revealed several important facts about HIP1 that implicate it in a significantly in the pathogenesis of Huntington’s Disease. First, as shown in Fig. 1, it was found that the native interaction between HD protein and HIP1 is influenced by the number of CAG repeats. Second, it was found that expression of the HIP1 protein is enriched in the brain. The highest amounts of expression are in the cortex, with lower levels being seen in the cerebellum, caudate and putamen.
It has also been observed that huntingtin proteins with expanded polyglutamine tracts can aggregate into large, irregularly shaped deposits in HD brains, transgenic mice and in vitro cell culture. We have shown that in HEK (human embryonic kidney) 293T cells, the aggregation of full-length and smaller huntingtin fragments occurs after the cells have been exposed to a period of apoptotic stress. Martindale, et al., Nature Genetics 18: 150-154 (1998). In order to assess the consequence of HIP1 expression in cultured cells, we used huntingtin aggregation as one marker of viability. What we found was that cells cotransfected with huntingtin (128 CAG repeats) and HIP1 contained aggregates comparable to those observed following application of apoptotic stress with sub-lethal doses of tamoxifen in 14% of the cells, and that these cells were the ones in which both genes had been introduced as reflected by a double marker experiment. Transfection of a gene encoding a fusion protein of 128 repeat huntingtin and the DED domain from HIP1 ligated in the sense orientation resulted in aggregate formation in 30 to 50% of the cells.

The implications of the apoptotic activity of HIP1 are two-fold. First, the fact that this activity is apparently differentially modulated by interaction with huntingtin having normal and expanded repeats implicates HIP1 in the apoptotic neuronal death which is observed in Huntington’s disease and makes HIP1 a logical target for therapy. A second implication of the apoptotic activity of HIP1 is the potential for use of HIP1 as a therapeutic agent to introduce apoptosis in cancer cells.

Therapeutic targeting of HIP1 or other HIP-apoptosis modulating proteins might take any of several forms, but will in general be a treatment involving administration of a composition that reduces the apoptotic activity of the HIP-apoptosis modulating protein. As used in the specification and claims hereof, the term "administration" includes direct administration of a composition active to reduce apoptotic activity as well as indirect administration which might include administration of pro-drugs or nucleic acids that encode the desired therapeutic composition.

One class of composition which can be used in the therapeutic methods of the invention are those compositions which interfere with the activity of HIP-apoptosis modulating proteins by binding to the proteins and mask and reduce the interaction of HIP-apoptosis modulating proteins with the death signaling complex. Within this class of
compositions are normal (non-expanded) huntingtin, administered, for example, via increased expression of exogenous HD genes; the HIP-binding region of huntingtin, administered via gene therapy techniques; and other DED-interacting peptides. Other DED-interacting peptides which might be used in a therapeutic method of this type include FADD (Beldin et al., *Cell* 85: 803-815 (1996)) and caspase 8 (Muzio et al., *Cell* 85: 817-827 (1996)).

An alternative form of therapy involves the use of a mutant form of HIP1 or other HIP-apoptosis modulating protein from which the DED has been deleted. DED-containing proteins, including HIP1 are self-associating, and this self-association has been shown to be important for activity. (Muzio et al., *Cell* 85: 817-827 (1996). Thus, a protein with a deleted DED may compete with endogenous HIP-protein in the formation of these associations, thereby reducing the amount of apoptotic-ally active HIP-protein.

In addition to HIP1, we have identified a further human protein, HIP1a, from a human frontal cortex cDNA library. HIP1a is a family member of HIP1, and thus a HIP-apoptosis modulator in accordance with the invention. A partial sequence of HIP1a (the 5' portion of HIP1a remains to be characterized) is given by SEQ ID Nos. 6 and 7. The isolated and characterized portion of HIP1a shows 53% nucleotide identity and 58% amino acid conservation with HIP1 (Table 1, Figs. 2 and 3).

We have also isolated 2 mouse proteins mHIP1 and mHIP1a (SEQ. ID Nos. 8-11) which appear to be the murine homologues of human HIP1 and HIP1a. As in the case of human HIP1a, the 5' portion of mHIP1 remains to be isolated. At present, mHIP1 shows 85% nucleotide identity and 90% amino acid conservation with huHIP1 (Table 1, Figs. 2 and 3). mHIP1a shows 60% nucleotide identity and 61% amino acid conservation with huHIP1 (Table 1, Figs. 2 and 3). mHIP1a shows stronger homology to huHIP1a; it shows 87% nucleotide identity and 91% amino acid conservation with huHIP1a (Table 1, Figs. 2 and 3).

Taken together these findings indicate that mHIP1 is the murine homologue of huHIP1 whereas mHIP1a is most likely the murine homologue of huHIP1a. As mentioned previously, HIP1 shows sequence similarity to Sla2p in S. cerevisiae and the hypothetical protein ZK370.3 in C. elegans. Similarly, huHIP1a, mHIP1, and mHIP1a show sequence similar to Sla2p and ZK370.3 (Table 2). The carboxy-terminal regions of huHIP1a, mHIP1, and mHIP1a all show considerable homology to the mammalian membrane
cytoskeletal-associated protein, talin. This suggests that these 3 proteins may also play a role in the regulation of membrane events through interactions with the underlying cytoskeleton.

HIP1 contains a death effector domain (DED), a domain which is also present in a number of proteins involved in the apoptotic pathway (Fig. 4). This suggests that HIP1 may act as a modulator of the apoptosis pathway. The DED in huHIP1 is present between amino acid positions 287 and 368. Similarly, HIP1a, mHIP1, and mHIP1a also contain a DED. In huHIP1a the DED is present at amino acids 1-78 of the recovered fragment. In mHIP1 and mHIP1a, the DED are present at amino acids 128-210 and 388-470, respectively. The DED present in huHIP1a, mHIP1 and mHIP1a all show significant percentage amino acid conservation to the DED present in huHIP1 (Table 3).

Increasing expression of normal (non-expanded) huntingtin or the HIP-apoptotic modulator-binding portion thereof, a modified HIP-apoptotic modulator in which the DED has been deleted or of a DED-interacting protein or peptide can be accomplished using gene therapy approaches. In general, this will involve introduction of DNA encoding the appropriate protein or peptide in an expressable vector into the brain cells. Expression of HIP-apoptosis modulating proteins may also be useful in treatment of cancer in which case application to other cell types would be desired, and cells expressing HIP-apoptosis modulating proteins may be used for screening of therapeutic compounds. Thus, in a more general sense, expression vectors are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate cell type. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector may contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.

A variety of mammalian expression vectors may be used to express recombinant

The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, infection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce the desired protein. Delivery of retroviral vectors to brain and nervous system tissue has been described in US Patents Nos. 4,866,042, 5,082,670 and 5,529,774, which are incorporated herein by references. These patents disclose the use of cerebral grafts or implants as one mechanism for introducing vectors bearing therapeutic gene sequences into the brain, as well as an approach in which the vectors are transmitted across the blood brain barrier.

To further illustrate the methods of making the materials which are the subject of this invention, and the testing which has established their utility, the following non-limiting experimental procedures are provided.
EXAMPLE 1

IDENTIFICATION OF INTERACTING PROTEINS

GAL4-HD cDNA constructs

An HD cDNA construct (44pGBT9), with 44 CAG repeats was generated

encompassing amino acids 1 - 540 of the published HD cDNA. This cDNA fragment was
fused in frame to the GAL4 DNA-binding domain (BD) of the yeast two-hybrid vector
pGBT9 (Clontech). Other HD cDNA constructs, 16pGBT9, 80pGBT9 and 128pGBT9 were
constructed, identical to 44pGBT9 but included only 16, 80 or 128 CAG repeats,
respectively.

Another clone (DMKDBamHIpGBT9) containing the first 544 amino acids of the
myotonic dystrophy gene (a gift from R. Korneluk) was fused in-frame with the GAL4-DNA
BD of pGBT9 and was used as a negative control. Plasmids expressing the GAL4-BDRAD7
(D. Gietz, unpublished) and SIR3 were used as a positive control for the β-galactosidase filter
assay.

The clones IT15-23Q, IT15-44Q and HAP1 were generous gifts from Dr. C. Ross.
These clones represent a previously isolated huntingtin interacting protein that has a higher
affinity for the expanded form of the HD protein.

Yeast strains, transformations and β-galactosidase assays

The yeast strain Y190 (MATa leu2-3,112, ura3-52, trp1-901, his3-Δ200, ade2-101,
gal4Δgal80Δ, URA3::GAL-lacZ, 1.YS2::GAL-HIS3,cyc1) was used for all transformations
and assays. Yeast transformations were performed using a modified lithium acetate
transformation protocol and grown at 30 C using appropriate synthetic complete (SC) dropout
media.

The β-galactosidase chromogenic filter assays were performed by transferring the
yeast colonies onto Whatman filters. The yeast cells were lysed by submerging the filters in
liquid nitrogen for 15-20 seconds. Filters were allowed to dry at room temperature for at
least five minutes and placed onto filter paper presoaked in Z-buffer (100 mM sodium
phosphate (pH7.0) 10 mM KCl, 1 mM MgSO4) supplemented with 50 mM
2-mercaptoethanol and 0.07 mg/ml 5-bromo-4-chloro-3-indoly1 β-D-galactoside (X-gal). Filters were placed at 37 C for up to 8 hours.

**Yeast two-hybrid screening for huntingtin interacting protein (HIP)**

CDNAs from an human adult brain Matchmaker™ cDNA library (Clontech) was transformed into the yeast strain Y190 already harboring the 44pGBT9 construct. The transformants were plated onto one hundred 150 mm x 15 mm circular culture dishes containing SC media deficient in Trp, Leu and His. The herbicide 3-amino-triazole (3-AT) (25mM) was utilized to limit the number of false His+ positives (31). The yeast transformants were placed at 30 C for 5 days and β-galactosidase filter assays were performed on all colonies found after this time, as described above, to identify β-galactosidase+ clones. Primary His+/β-galactosidase+ clones were then orderly patched onto a grid on SC-Trp/-Leu/-His (25 mM 3AT) plates and assayed again for His+ growth and the ability to turn blue with a filter assay. Secondary positives were identified for further analysis. Proteins encoded by positive cDNAs were designated as HIPs (Huntingtin Interactive Proteins). Approximately 4.0 x 10^7 Trp/Leu auxotrophic transformants were screened and of 14 clones isolated 12 represented the same cDNA (HIP1), and the other 2 cDNAs, HIP2 and HIP3 were each represented only once.

The HIP cDNA plasmids were isolated by growing the His+/β-galactosidase+ colony in SC-Leu media overnight, lysing the cells with acid-washed glass beads and electroporating the bacterial strain, KC8 (leuB auxotrophic) with the yeast lysate. The KC8 ampicillin resistant colonies were replica plated onto M9 (-Leu) plates. The plasmid DNA from M9+ colonies was transformed into DH5-a for further manipulation.

**EXAMPLE 2**

CONFIRMATION OF INTERACTIONS

The HIP1-GAL4-AD cDNA activated both the lac-Z and His reporter genes in the yeast strain Y190 only when co-transformed with the GAL4-BD-HD construct, but not the negative controls (Fig. 1) of the vector alone or a random fusion protein of the myotonin kinase gene. In order to assess the influence of the polyglutamine tract on the interaction
between HIP1 and HD, semi-quantitative β-galactosidase assays were performed. GAL4-BD-HD fusion proteins with 16, 44, 80 and 128 glutamine repeats were assayed for their strength of interaction with the GAL4-AD-HIP1 fusion protein.

Liquid β-galactosidase assays were performed by inoculating a single yeast colony into appropriate synthetic complete (SC) dropout media and grown to OD600 0.6-1.5. Five millilitres of overnight culture was pelleted and washed once with 1 ml of Z-Buffer, then resuspended in 100 ml Z-Buffer supplemented with 38 mM 2-mercaptoethanol, and 0.05% SDS. Acid washed glass beads (~100 ml) were added to each sample and vortexed for four minutes, by repeatedly alternating a 30 seconds vortex, with 30 seconds on ice. Each sample was pelleted and 10 ml of lysate was added to 500 ml of lysis buffer. The samples were incubated in a 30 C waterbath for 30 seconds and then 100 ml of a 4 mg/ml o-nitrophenyl b-D galactopyranoside (ONPG) solution was added to each tube. The reaction was allowed to continue for 20 minutes at 30 C and stopped by the addition of 500 ml of 1 M Na2CO3 and placing the samples on ice. Subsequently, OD420 was taken in order to calculate the β-galactosidase activity with the equation 1000 x OD420/(t x V x OD600) where t is the elapsed time (minutes) and V is the amount of lysate used.

The specificity of the HIP1-HD interaction can be observed using the chromogenic filter assay. Only yeast cells harboring HIP1 and HD activate both the HIS and lacZ reporter genes in the Y190 yeast host. The cells that contain the HIP1 with HD constructs with 80 or 128 CAG repeats turn blue approximately 45 minutes after the cells with the smaller sized repeats (16 or 44).

No difference in the β-galactosidase activity was observed between the 16 and 44 repeats or between the 80 and 128 repeats. However, a significant difference (p<0.05) in activity is seen between the smaller repeats (16 and 44) and the larger repeats (80 and 128).

(Figure 1)

EXAMPLE 3

DNA SEQUENCING, cDNA ISOLATION AND 5' RACE

Oligonucleotide primers were synthesized on an ABI PCR-mate oligo-synthesizer. DNA sequencing was performed using an ABI 373 fluorescent automated DNA sequencer.
The HIP cDNAs were confirmed to be in-frame with the GAL4-AD by sequencing across the AD-HIP1 cloning junction using an AD oligonucleotide (5'GAA GAT ACC CCA CCA AAC3'). (Seq. ID No. 12)

Subsequently, primer walking was used to determine the remaining sequences. A human frontal cortex >4.0 kb cDNA library (a gift from S. Montal) was screened to isolate the full length HIP1 gene. Fifty nanograms of a 558 base pair Eco RI fragment from the original HIP1 cDNA was radioactively labeled with [α32P]-dCTP using nick-translation and the probe allowed to hybridized to filters containing >105 pfu/ml of the cDNA library overnight at 65°C in Church buffer (see Northern blot protocol). The filters were washed at 65°C for 10 minutes with 1 X SSPE, 15 minutes at 65 C with 1 X SSPE and 0.1% SDS, then for thirty minutes and fifteen minutes with 1 X SSPE and 0.1% SDS. The filters were exposed to X-ray film (Kodak, XAR5) overnight at ~70 C. Primary positives were isolated and replated and subsequent secondary positives were hybridized and washed as for the primary screen. The resulting positive phage were converted into plasmid DNA by conventional methods (Stratagene) and the cDNA isolated and sequenced.

In order to obtain the most 5' sequence of the HIP1 gene, a Rapid Amplification of cDNA Ends (RACE) protocol was performed according to the manufacturers recommendations (BRL). First strand cDNA was synthesized using the oligo HIP1-242R (5' GCT TGA CAG TGT AGT CAT AAA GGT GGC TGC AGT CC 3'). (Seq. ID No. 13)

After dCTP tailing the cDNA with terminal deoxy transferase, two rounds of 35 cycles (94°C 1 minute; 53°C 1 minute; 72°C 2 minutes) of PCR using HIP1-R2 (5' GGA CAT GTC CAG GGA GTT GAA TAC 3') (Seq. ID No. 14) and an anchor primer (5' (CUA)4 GGC CAC GCG TCG ACT AGT ACG GGI IGG GI GGG IIG3') (BRL ,Seq. ID No. 15)) were performed. The subsequent 650 base pair PCR product was cloned using the TA cloning system (Invitrogen) and sequenced using T3 and T7 primers. Sequences ID Nos. 1 and 3 show the sequence of the HIP1 cDNAs obtained.
EXAMPLE 4

DNA AND AMINO ACID ANALYSES

Overlapping DNA sequence was assembled using the program MacVector and sent via email or Netscape to the BLAST server at NIH (http://www.ncbi.nlm.nih.gov) to search for sequence similarities with known DNA (blastn) or protein (tblastn) sequences. Amino acid alignments were performed with the program Clustalw.

EXAMPLE 5

FISH DETECTION SYSTEM AND IMAGE ANALYSIS

The HIP1 cDNA isolated from the two-hybrid screen was mapped by fluorescent in situ hybridization (FISH) to normal human lymphocyte chromosomes counterstained with propidium iodide and DAPI. Biotinylated probe was detected with avidin-fluorescein isothiocyanate (FITC). Images of metaphase preparations were captured by a thermoelectrically cooled charge coupled camera (Photometrics). Separate images of DAPI banded chromosomes and FITC targeted chromosomes were obtained. Hybridization signals were acquired and merged using image analysis software and pseudo colored blue (DAPI) and yellow (FITC) as described and overlaid electronically. This study showed that HIP1 maps to a single genomic locus at 7q11.2.

EXAMPLE 6

NORTHERN BLOT ANALYSIS

RNA was isolated using the single step method of homogenization in guanidinium isothiocyanate and fractionated on a 1.0% agarose gel containing 0.6 M formaldehyde. The RNA was transferred to a hybond N-membrane (Amersham) and crosslinked with ultraviolet radiation.

Hybridization of the Northern blot with β-actin as an internal control probe provided confirmation that the RNA was intact and had transferred. The 1.2 kb HIP1 cDNA was labeled using nick translation and incorporation of α-32P-DCTP. Hybridization of the original 1.2 kb HIP1 cDNA was carried out in Church buffer (0.5 M sodium phosphate buffer, pH 7.2, 2.7% sodium dodecyl sulphate, 1 mM EDTA) at 55 C overnight. Following
hybridization, Northern blots were washed once for 10 minutes in 2.0 X SSPE, 0.1% SDS at room temperature and twice for 10 minutes in 0.15 X SSPE, 0.1% SDS. Autoradiography was carried out from one to three days using Hyperfilm (Amersham) film at -70 C.

Analysis of the levels of RNA levels of HIP1 by Northern blot data revealed that the 10 kilo base HIP1 message is present in all tissue assessed. However, the levels of RNA are not uniform, with brain having highest levels of expression and peripheral tissues having less message. No apparent differences in RNA expression was noted between control samples and HD affected individuals.

EXAMPLE 7

TISSUE LOCALIZATION OF HIP1

Tissue localization of HIP1 was studied using a variety of techniques as described below. Subcellular distribution of HIP-1 protein in adult human and mouse brain Biochemical fractionation studies revealed the HIP1 protein was found to be a membrane-associated protein. No immunoreactivity was seen by Western blotting in cytosolic fractions, using the anti-HIP1-pep1 polyclonal antibody. HIP1 immunoreactivity was observed in all membrane fractions including nuclei (P1), mitochondria and synaptosomes (P2), microsomes and plasma membranes (P3). The P3 fraction contained the most HIP1 compared to other membrane fractions. HIP1 could be removed from membranes by high salt (0.5M NaCl) buffers indicating it is not an integral membrane protein, however, since low salt (0.1-0.25M NaCl) was only able to partially remove HIP1 from membranes, its membrane association is relatively strong. The extraction of P3 membranes with the non-ionic detergent, Triton X-100 revealed HIP1 to be a Triton X-100 insoluble protein. This characteristic is shared by many cytoskeletal and cytoskeletal-associated membrane proteins including actin, which was used as a control in this study. The biochemical characteristics of HIP1 described were found to be identical in mouse and human brain and was the same for both forms of the protein (both bands of the HIP1 doublet). HIP1 co-localized with huntingtin in the P2 and P3 membrane fractions, including the high-salt membrane extractions, as well as in the Triton X-100 insoluble residue. The subcellular distribution of HIP1 was unaffected by the
expression of polyglutamine-expanded huntingtin in transgenic mice and HD patient brain samples.

The localization of HIP1 protein was further investigated by immunohistochemistry in normal adult mouse brain tissue. Immunoreactivity was seen in a patchy, reticular pattern in the cytoplasm, appeared excluded from the nucleus and stained most intensely in a discontinuous pattern at the membrane. These results are consistent with the association of HIP1 with the cytoskeletal matrix and further indicate an enrichment of HIP1 at plasma membranes. Immunoreactivity occurred in all regions of the brain, including cortex, striatum, cerebellum and brainstem, but appeared most strongly in neurons and especially in cortical neurons. As described previously, huntingtin immunoreactivity was seen exclusively and uniformly in the cytosol.

The in situ hybridization studies showed HIP1 mRNA to be ubiquitously and generally expressed throughout the brain. This data is consistent with the immunohistochemical results and was identical to the distribution pattern of huntingtin mRNA in transgenic mouse brains expressing full-length human huntingtin.

Protein Preparation And Western Blotting For Expression Studies

Frozen human tissues were homogenized using a Polytron in a buffer containing 0.25M sucrose, 20mM Tris-HCl (pH 7.5), 10mM EGTA, 2mM EDTA supplemented with 10ug/ml of leupeptin, soybean trypsin inhibitor and 1mM PMSF, then centrifuged at 4,000rpm for 10' at 4 C to remove cellular debris. 100-150ug/lane of protein was separated on 8% SDS-PAGE mini-gels and then transferred to PVDF membranes. Huntingtin and HIP1 were electroblotted overnight in Towbin's transfer buffer (25 mM Tris-HCl, 0.192M glycine, pH8.3, 10% methanol) at 30V onto PVDF membranes (Immobilon-P, Millipore) as described (Towbin et al, Proc. Nat'l Acad. Sci.(USA) 76: 4350-4354 (1979)). Membranes were blocked for 1 hour at room temperature in 5% skim milk/ TBS (10mM Tris-HCl, 0.15M NaCl, pH7.5). Antibodies against huntingtin (pAb BKPl, 1:500), actin (mAb A-4700, Sigma, 1:500) or HIP1 (pAb HIP-pep1, 1:200) were added to blocking solution for 1 hour at room temperature. After 3 x 10 minutes washes in TBS-T (0.05% Tween-20/TBS), secondary Ab (horseradish peroxidase conjugated IgG, Biorad) was applied in blocking solution for 1 hour
at room temperature. Membranes were washed and then incubated in chemiluminescent ECL solution and visualized using Hyperfilm-ECL film (Amersham).

Generation of Antibodies

The generation of huntingtin specific antibodies GHM1 and BKP1 is described elsewhere (Kalchman, et al., *J. Biol. Chem.* 271: 19385-19394 (1996)). The HIP1 peptide (VLEKDDLMDMDASQQN, a.a. 76-91 of Seq. ID No. 2) was synthesized with Cys on the N-terminus for the coupling, and coupled to Keyhole limpet hemocyanin (KLH) (Pierce) with succinimidy 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (Pierce). Female New Zealand White rabbits were injected with HIP1 peptide-KLH and Freund's adjuvant. Antibodies against the HIP1 peptide were purified from rabbit sera using affinity column with low pH elution. Affinity column was made by incubation of HIP1 peptide with activated thio-Sepharose (Pharmacia).

Western blotting of various peripheral and brain tissues were consistent with the RNA data. The HIP1 protein levels observed was not equivalent in all tissues. The protein expression is predominant in brain tissue, with highest amounts seen in the cortex and lower levels seen in the cerebellum and caudate and putamen.

More regio-specific analysis of HIP1 expression in the brain revealed no differential expression pattern in affected individuals when compared to normal controls, with highest levels of expression seen in both controls and HD patients in the cortical regions.

**EXAMPLE 8**

**CO-IMMUNOPRECIPITATION OF HIP1 WITH HUNTINGTIN**

Confirmation of the HD-HIP1 interaction was performed using coimmunoprepitation as follows. Control human brain (frontal cortex) lysate was prepared in the same manner as for subcellular localization study. Prior to immunoprecipitation, tissue lysate was centrifuged at 5000 rpm for 2 minutes at 4°C, then the supernatant was pre-cleared by the incubated with excess amount of Protein A-Sepharose for 30 minutes at 4°C, and centrifuged at the same condition. Fifty microlitres of supernatant (500 mg protein) was incubated with or without antibodies (10 ug of anti-huntingtin GHM1 (Kalchman, et al. 1996) or anti-synaptobrevin antibody) in the total 500 ul of incubation buffer (20mM Tris-Cl
(pH 7.5), 40mM NaCl, 1mM MgCl₂) for 1 hour at 4°C. Twenty microlitres of Protein A-Sepharose (1:1 suspension, for GHM1 and no antibody control) or Protein G-Sepharose (for anti-synaptobrevin antibody; Pharmacia) was added and incubated for 1 hour at 4°C. The beads were washed with washing buffer (incubation buffer containing 0.5% Triton X-100) three times. The samples on the beads were separated using SDS-PAGE (7.5% acrylamide) and transferred to PVDF membrane (Immobilon-P, Millipore). The membrane was cut at about 150 kDa after transfer for Western blotting (as described above). The upper piece was probed with anti-huntingtin BKP1 (1/1000) and lower piece with anti-HIP1 antibody (1/300).

The results showed that when an anti-HIP1 polyclonal antibody was immunoreacted against a blot containing the GHM1 immunoprecipitates from the brain lysate a doublet was observed at approximately 100 kDa. When GHM1 was immunoreacted against the same immunoprecipitate the 350 kDa HD protein was also seen. The specificity of the HD-HIP1 interaction is seen as no immunoreactive bands seen are as a result of the proteins adsorbing to the Protein-A-Sepharose (Lysate + No Antibody) or when a random, non related antibody (Lysate + anti-Synaptobrevin) is used as the immunoprecipitating antibody.

EXAMPLE 9

Subcellular fractionation of brain tissue

Cortical tissue (20-100 mg/ml) was homogenized, on ice, in a 2 ml pyrex-teflon IKA-RW15 homogenizer (Tekmar Company) in a buffer containing 0.303M sucrose, 20mM Tris-HCl pH 6.9, 1mM MgCl₂, 0.5mM EDTA, 1mM PMSF, 1mM leupeptin, soybean trypsin inhibitor and 1mM benzamidine (Wood et al., *Human Molec. Genet.* 5: 481-487 (1996)).

Crude membrane vesicles were isolated by two cycles of a three-step differential centrifugation protocol in a Beckman TLA 120.2 rotor at 4°C based on the methods of Wood et al (1996). The first step precipitated cellular debris and nuclei from tissue homogenates for 5 minutes at 1300 x g (P1). The 1300 x g supernatant was subsequently centrifuged for 20 minutes at 14,000 x g to isolate synaptosomes and mitochondria (P2). Finally, microsomal
and plasma membrane vesicles were collected by a 35 minute centrifugation at 142 000 x g (P3). The remaining supernatant was defined as the cytosolic fraction.

**High salt extraction of membranes**

Aliquots of P3 membranes were twice suspended at 2mg/ml in 0.5M NaCl, 10mM Tris-HCl, 2mM MgCl₂, pH 7.2, containing protease inhibitors (see above). The same buffer without NaCl was used as a control. The membrane suspensions were incubated on ice for 30 minutes and then centrifuged at 142 000 x g for 30 minutes.

**Extraction of cytoskeletal and cytoskeletal-associated proteins.**

To extract cytoskeletal proteins, crude membrane vesicles from the P3 fraction membrane were suspended in a volume of Triton X-100 extraction buffer to give a protein: detergent ratio of 5:1. The composition of the Triton X-100 extraction buffer was based on the methods of Arai et al., *J. Neuroscience* 38: 348-357 (1994) and contained 2% Triton X-100, 10mM Tris-HCl, 2mM MgCl₂, 1mM leupeptin, soybean trypsin inhibitor, PMSF and benzamidine. Membrane pellets were suspended by hand with a round-bottom teflon pestle, and placed on ice for 40 minutes. Insoluble cytoskeletal matrices were precipitated for 35 minutes at 142 000 x g in a Beckman TLA 120.2 rotor. The supernatant was defined as non-cytoskeletal-associated membrane or membrane-associated protein and was removed. The remaining pellet was extracted with Triton X-100 a second time using the same conditions. We defined the final pellet as cytoskeletal and cytoskeletal-associated protein.

**Solubilization of protein and analysis by SDS-PAGE and Western Blotting**

Membrane and cytoskeletal protein was solubilized in a minimum volume of 1% SDS, 3M urea, 0.1mM dithiothreitol in TBS buffer and sonicated. Protein concentration was determined using the BioRad DC Protein assay and samples were diluted at least 1 X with 5 X sample buffer (250mM Tris-HCl pH 6.8, 10% SDS, 25% glycerol, 0.02% bromophenol blue and 7% 2-mercaptoethanol) and were loaded on 7.5% SDS-PAGE gels (Bio-Rad Mini-PROTEIN II Cell system) without boiling. Western blotting was performed as described above.
**Immunohistochemistry**

Brain tissue was obtained from a normal C57BL/6 adult (6 months old) male mouse sacrificed with chloroform then perfusion-fixed with 4% v/v paraformaldehyde/0.01 M phosphate buffer (4% PFA). The brain tissues were removed, immersion fixed in 4% PFA for 1 day, washed in 0.01M phosphate buffered saline, pH 7.2 (PBS) for 2 days, and then equilibrated in 25% w/v sucrose PBS for 1 week. The samples were then snap-frozen in Tissue Tek molds by isopentane cooled in liquid nitrogen. After warming to -20°C, frozen blocks derived from frontal cortex, caudate/putamen, cerebellum and brainstem were cut into 14 mm sections for immunohistochemistry. Following washing in PBS, the tissue sections were blocked using 2.5% v/v normal goat serum for 1 hour at room temperature. Primary antibodies diluted with PBS were applied to sections overnight at 4°C. Optimal dilutions for the polyclonal antibodies BKp1 and HIP1 were 1:50. Using washes of 3 x 5 minutes in PBS at room temperature, sections were sequentially incubated with biotinylated secondary antibody and then an avidin-biotin complex reagent (Vecta Stain ABC Kit, Vector) for 60 minutes each at room temperature. Color was developed using 3,3'-diaminobenzidine tetrahydrochloride and ammonium nickel sulfate.

For controls, sections were treated as described above except that HIP1 antibody aliquots were preabsorbed with an excess of HIP1 peptide as well as a peptide unrelated to HIP1 prior to incubation with the tissue sections.

**In situ hybridization**

In situ hybridization was performed as previously described with some modification (Suzuki et al, *BBRC* 219: 708-713 (1996)). The RNA probes were prepared using the plasmid gt149 (Lin, B., et al., *Human Molec. Genet.* 2: 1541-1545 (1994)) or a 558 subclone of HIP1. The anti-sense and sense single-stranded RNA probes were synthesized using T3 and T7 RNA polymerases and the In Vitro Transcription Kit (Clontech) with the addition of \([α^35]S\)-CTP (Amersham) to the reaction mixture. Sense RNA probes were used as negative controls. For HIP1 studies normal C57BL/6 mice were used. Huntingtin probes were tested on two different transgenic mouse strains expressing full-length huntingtin, cDNA HD10366 (44CAG) C57BL/6 mice and YAC HD10366(18CAG) FVB/N mice. Frozen brain sections
(10μm thick) were placed onto silane-coated slides under RNase-free conditions. The hybridization solution contained 40% w/v formamide, 0.02M Tris-HCl (pH 8.0), 0.005M EDTA, 0.3 M NaCl, 0.01M sodium phosphate (pH 7.0), 1x Denhardt's solution, 10% w/v dextran sulfate (pH 7.0), 0.2% w/v sarcosyl, yeast tRNA (500mg/ml) and salmon sperm DNA (200mg/ml). The radiolabelled RNA probe was added to the hybridization solution to give 1 x 106 cpm/200 ul/ section. Sections were covered with hybridization solution and incubated on formamide paper at 65 C for 18 hours. After hybridization, the slides were washed for 30 minutes sequentially with 2x SSC, 1x SSC and high stringency wash solution (50% formamide, 2x SSC and 0.1M dithiothreitol) at 65 C, followed by treatment with RNAse A (1mg/ml) at 37 C for 30 minutes, then washed again and air-dried. The slides were first exposed on autoradiographic film (b-max, Amersham, UK) for 48 hours and developed for 4 minutes in Kodak D-19 followed by a 5 minute fixation in Fuji-fix. For longer exposures, the slides were dipped in autoradiographic emulsion (50% w/v in distilled water, NR-2, Konica, Japan), air-dried and exposed for 20 days at 4 C then developed as described. Sections were counterstained with methyl green or Giemsa solutions.

**EXAMPLE 10**

We determined a more precise location of the HIP1 gene on chromosome 7 in the context of a physical and genetic map of chromosome 7, and determined its genomic organization. HIP1 maps by FISH and RH mapping to chromosome band 7q11.23, which contains the chromosomal region commonly deleted in Williams-Beuren syndrome (WS). We used several methods to refine the mapping of HIP1 in this region. PCR screening of a chromosome 7-YAC-library (Scherer et al., *mammalian Genome* 3: 179-181 (1992)) with primers from the 3' UTR of HIP1 resulted in the identification of only a single positive YAC clone (HSC7E512). This YAC clone had previously been shown to map near the Williams syndrome commonly deleted region (Osborne et al., *Genomics* 45: 402-406 (1997)). The HIP1 cDNA was then used to screen a chromosome 7 specific cosmid library from the Lawrence Livermore National Laboratory (LL07NC01), and the RPCI genomic P1 derived artificial chromosome (PAC) library (Pieter de Jong, Roswell Park, Buffalo, NY). Several PAC and cosmid clones that were already part of pre-assembled contigs in the Williams
syndrome region at 7q11.23 were identified (Fig 5). Restriction enzyme digestion, blot hybridization experiments and PCR screening confirmed that the clones contained the HIP1 gene.

We determined the exon-intron boundaries and intron sizes of HIP1. Primers were designed based on the sequence of the HIP1 transcript and used to sequence directly from the cosmid, PAC clone and long PCR products from PAC or genomic DNA. Whenever a PCR fragment generated was longer than predicted from the cDNA sequence, it was assumed to contain an intron. The size of the introns was determined by sequencing the intron directly or by PCR amplification of the introns from both genomic DNA and the cosmid or PAC clone from the region. Three sets of overlapping cosmids and a PAC clone that contain the entire coding sequence of HIP1 were characterized (Fig 5). Cosmid 181G10 and 250F2 were digested with EcoRI and cloned into the plasmid bluescript. Further sequences were generated from these plasmid subclones. Intron-exon boundary sequences were then identified by comparing HIP1 genomic and transcript sequence. The gene is contained within 75 kb and comprises 29 exons and 28 introns. The intron-exon boundary sequences are shown in Table 4, along with the exon and intron sizes. A graphic summary of these data is also shown in Fig. 5. Exons 1 to 28 contained the coding regions. The last and largest exon of the HIP1 gene was found to contain approximately 7 kb. Most of the intron-exon junctions followed the canonical GT-AG rule. An AT was found at the 3' splice site of exon 1 and an AC at the 5' splice site of exon 2. Sequence data from all the exon-intron borders of the coding region and 3'-UTR is set forth in Seq. ID Nos. 16-44. (These sequence have been deposited with GenBank as Accession Nos. AF052261 to AF052288).

Sequence analysis of previously published 5' untranslated region (GenBank accession U79734) revealed the possibility that the open reading frame extends upstream of the ATG in the exon 4 to a 5' ATG in exon 1. Although we failed to obtain any additional 5' sequences despite repeated 5' RACE analyses, an additional ATG, 284 bp upstream of the previously published exon 1 is in the same reading frame and has the surrounding sequence of TGCCATGT TT which is similar to the AGCCATGGG, the consensus Kozak sequence (Kozak, M. *Nucl. Acids Res.* 15: 8125-8148 (1987)). If translated from this ATG, the protein would be highly homologous to the N-terminal portion of ZK370.3 and yeast Sla2 protein
The translated protein in the region of exons 1 to 3 shows an identity of >40% and similarity of >60% to the N-terminal part of ZK370.3. This suggests that the exons 1 to 3 are probably translated.

In western blot studies, HIP1 is identified as a 120 kd protein (11, 23), while the putative translation of the previously published cDNA gives a protein product of estimated molecular weight of approximately 100 kd. If HIP1 gene were translated from the ATG 284 bp upstream of the exon 1, the expected product would have an estimated molecular weight of 122 kd. RNA PCR studies with primers downstream of this ATG and primers in exon 7 amplify expected products of 576 and 600 bp. Taken together these data support the contention that exon 1 extends further 5' and that HIP1 gene is translated from the ATG in exon 1. Sequence analyses showed no TATA, CAAT box or any GC rich promoter sequence upstream of exon 1 ATG. The promoter prediction programs provided by the server http://dot.imgen.bcm.tmc.edu:9331/seq.search/gene.search.html did not predict any promoter upstream of the ATG at position -284, (position 0 corresponds to the first nucleotide of published cDNA, GenBank accession U79734). This suggests that HIP1 may have additional exons.

Finally, we evaluated HIP1 gene as a candidate gene for Huntington disease in families without CAG expansion. In a large study of 1022 patients with a clinical diagnosis of HD, no CAG repeat expansion was found in 12 patients who might represent phenocopies of HD. In at least three families, linkage studies have excluded the HD locus at 4p.

Mutation in an interacting protein could result in a similar phenotype as illustrated by the discovery of mutations in dystrophin associated proteins in muscular dystrophies. A mutation in HIP1 may result in altered interaction of huntingtin and HIP1 and lead to cellular toxicity as a result of more HIP1 being free in the cytosol. Thus mutations in huntingtin interacting proteins genes may cause a phenotype suggestive of HD. We studied two of the larger families diagnosed with HD without CAG expansion in HD gene, with the highly informative marker D71816 which maps centromeric and very close to HIP1 gene. The clinical findings in both the families were compatible with a diagnosis of HD, although there were atypical features. In family 1733, HIP1 locus appears to be excluded, as there are two recombinants with the marker. Individuals II-5 and II-7 who do not share the haplotype with
the affected individuals are now 41 and 39 years old and have normal neurological examinations.

In the family 1602, a lod score of 1.92 is obtained with the marker D7S1816 at $\theta_{max}=0$. Sequencing of all the coding exons did not reveal any mutation in any exon sequence. The promoter sequence has not been examined. Subsequently a whole genome scan revealed a higher lod scores for markers on chromosome 20p.

**EXAMPLE 11**

A mouse brain lambda ZAPII cDNA library (Stratagene # 93609) was screened with various mouse ESTs which showed homology to the human HIP1 cDNA sequence (see Fig. 7). The ESTs were initially isolated from the non-redundant Database of GenBank EST Division by performing a BLASTN using a fragment of the human HIP1 cDNA as the query. We obtained 4 different ESTs which showed homology to HIP1: 1) aa110840 (clone 520282) which is 399bp and shows 58% identity, at the nucleotide level, to position 1880 to 2259 of the HIP1 cDNA. 2) w82687 (clone 404331) which is 420bp and shows 66% identity, at the nucleotide level, to position 2750 to 2915 of the HIP1 cDNA. 3) aa138903 (clone 586510) which is 509bp and shows 88% identity, at the nucleotide level, to position 2763 to 2832 of the HIP1 cDNA. 4) aa388714 (569088) which is 404bp and shows 88% identity, at the nucleotide level, to position 2475 to 2692 of the HIP1 cDNA.

**mHIP1**:

Fifty nanograms of a 362bp KpnI & PvuII fragment of clone 569088 (containing EST aa388714) was radioactively labeled with [32-P]-dCTP using random-priming. The probe was allowed to hybridize to filters containing $> 2 \times 10^5$ pfu/ml of the mouse brain lambda ZAPII cDNA library (Stratagene # 93609) overnight at 65°C in Church buffer (0.5M sodium phosphate buffer (pH 7.2), 2.7% SDS, 1mM EDTA). The filters were washed at room temperature for 15 minutes with 2XSSPE, 0.1% SDS, then at 65°C for 20 minutes with 1XSSPE, 0.1%SDS and finally twice at 65°C with 0.5 XSSPE, 0.1%SDS. The filters were exposed to X-ray film (Kodak, XAR5) overnight at ~70°C. Primary positives were isolated, replated and subsequent secondary positives were hybridized and washed as for the primary
screen. The resulting positive phage was converted into plasmid DNA by conventional methods (Stratagene) and the cDNA termed 4n-n1, was isolated and sequenced 551bp and 541bp from the T7 and T3 end, respectively. 4n-n1 is 2.2kb in length and the T7 end showed 72% identity, at the nucleotide level, to position 1486 to 1715 of the HIP1 cDNA. The 2.2kb insert from 4n-n1 was excised using EcoR1. Fifty nanograms of the 2.2kb insert was used to produced a radioactive probe and used to screen the mouse brain lambda ZAPII cDNA library (Stratagene # 93609) in the same manner as above. The resulting positive phage was converted into plasmid DNA by conventional methods (Stratagene) and the cDNA termed mHIP1a, was isolated and completely sequenced. mHIP1 is 2.3kb in length and showed 85% identity, at the nucleotide level, to position 726 to 3072 of the HIP1 cDNA.

mHIP1a:
Fifty nanograms of a 1.3kb EcoRI & NcoI fragment of clone 404331 (containing EST w82687) was radioactively labeled with [32-P]-dCTP using random--priming. The probe was allowed to hybridize to filters containing > 2 x 10^7 pfu/ml of the mouse brain lambda ZAPII cDNA library (Stratagene # 93609) overnight at 65°C in Church buffer (see above). The filters were washed at room temperature for 15 minutes with 2XSSPE, 0.1% SDS, then at 65°C for 20 minutes with 1XSSPE, 0.1%SDS and finally twice at 65°C with 0.2XSSPE, 0.1%SDS. The filters were exposed to X-ray film (Kodak, XAR5) overnight at -70°C.

Primary positives were isolated, replated and subsequent secondary positives were hybridized and washed as for the primary screen. The resulting positive phage was converted into plasmid DNA by conventional methods (Stratagene) and the cDNA termed mHIP1a, was isolated and completely sequenced. mHIP1a is 3.96 kb in length and shows 60% identity, at the nucleotide level, to position 12 to 2703 of the HIP1 cDNA.

EXAMPLE 12

HIP1a:
The entire mHIP1a cDNA sequence was used to screen the non-redundant Database of GenBank EST Division. We identified a human EST, T08283, which showed homology to
mHIP1a. T08383 (clone HIBBB80) is 391bp and shows 87% identity, at the nucleotide level, to position 2904 to 3113 of the mHIP1a cDNA.

Fifty nanograms of a 1.6kb HindIII & NotI fragment of clone 404331 (containing EST T08283) was radioactively labeled with [32-P]-dCTP using random-priming. The probe was allowed to hybridize to filters containing > 2x 105 pfu/ml of a human frontal cortex lambda cDNA library overnight at 65 C in Church buffer (see above). The filters were washed at 65 C for 10 minutes with 1XSSPE, 0.1% SDS, and then for 30 minutes and 15 minutes with 0.1XSSPE, 0.1%SDS. The filters were exposed to X-ray film (Kodak, XAR5) overnight at -70 C. Primary positives were isolated, replated and subsequent secondary positives were hybridized and washed as for the primary screen. The resulting positive phage was converted into plasmid DNA by conventional methods (Stratagene) and the cDNA termed HIP1a, was isolated and completely sequenced. HIP1a is 3.2 kb in length and shows 53% identity, at the nucleotide level, to position 876 to 3058 of the HIP1 cDNA.

EXAMPLE 13

Following the identification of a 1.2 kb partial human HIP-1 cDNA by yeast two-hybrid interaction studies, a 3.9 kb HIP-1 fragment was isolated from a cDNA library, ligated to a 5’ RACE product then subcloned into the mammalian expression vector pCI-neo (Promega). This construct, CMV-HIP-1, expresses HIP-1 from the CMV promoter and was used in the cell expression studies described below. Mouse HIP-1a (mHIP-1a) was also subcloned into a CMV driven expression vector for cell culture expression studies.

EXAMPLE 14

Huntingtin proteins with expanded polyglutamine tracts can aggregate into large, irregularly shaped deposits in HD brains, transgenic mice and in vitro cell culture. We have shown that in HEK (human embryonic kidney) 293T cells the aggregation of full-length and larger huntingtin fragments occurs after the cells have been exposed to a period of apoptotic stress. In order to assess the consequence of HIP-1 expression in cultured cells, we used huntingtin aggregation as one marker of viability.
Human embryonic kidney cells (HEK 293T) were grown on glass coverslips in Dulbecco's modified Eagle medium (DMEM, Gibco, NY) with 10% fetal bovine serum and antibiotics, in 5% CO2 at 37°C. The cells were transfected at 30% confluency with the calcium phosphate protocol by mixing Qiagen-prepared DNA (Qiagen, CA) with 2.5 M CaCl₂, then incubating at room temperature for 10 min. 2X HEPES buffer (240 mM NaCl, 3.0 mM Na₂HPO₄, 100 mM HEPES, pH 7.05) was added to the DNA/calcium mixture, incubated at 37°C for 60 sec, then added to the cells. After 12-18 h, the media was removed, the cells were washed and fresh media was added. At 36 h post-transfection, the cells were exposed to an apoptotic stress by treatment with 35 uM tamoxifen (Sigma) for 1 hour, or left untreated, then processed for immunofluorescence. The cells were washed with PBS, fixed in 4% paraformaldehyde/PBS solution for 20 minutes at room temperature then permeabilized in 0.5% Triton X-100/PBS for 5 min. Following three PBS washes, the cells were incubated with anti-huntingtin antibody MAB2166 (Chemicon) (1:2500 dilution) and anti-HIP-1 antibody HIP-1fp (1:100 dilution) in 0.4% BSA/PBS for 1 h at room temperature in a humidified container. The primary antibody was removed, the cells were washed and secondary antibodies conjugated to Texas red or FITC were added at a 1:600-1:800 dilution for 30 min at room temperature. The cells were then washed again, and the coverslips were mounted onto slides with DAPI (4',6'-diamindino-2 phenylindole, Sigma) as a nuclear counter-stain. Immunofluorescence was viewed using a Zeiss (Axioscope) microscope, digitally captured with a CCD camera (Princeton Instrument Inc.) and the images were colourized and overlapped using the Eclipse (Empix Imaging Inc.) software program. Appropriate control experiments were performed to determine the specificity of the antibodies, including secondary antibody only and mock transfected cells.

The huntingtin fragment HD1955 was used in the aggregation studies. This fragment represents the N-terminal 548 amino acids of huntingtin, and corresponds approximately to the polyglutamine-containing fragment produced by caspase 3 cleavage of huntingtin. Transfection of HD1955 with 15 polyglutamines (HD1955-15) results in a diffuse cytoplasmic distribution of the expressed protein. Transfection of HD1955 with 128 polyglutamines (HD1955-128) also results in diffuse cytoplasmic expression. However, exposure of cells transfected with HD1955-128 to tamoxifen results in a marked
redistribution of huntingtin. In 29% of cells expressing HD1955-128, the huntingtin protein appears as dense aggregates that are localized in the perinuclear area of the cell. In contrast, less than 1% of HD1955-128 expressing cells contain aggregates in the absence of tamoxifen, and 0% of HD1955-15 cells form aggregates in the presence or absence of tamoxifen treatment.

Co-transfection of HIP-1 and HD1955 was used to test the influence of HIP-1 on huntingtin aggregation. As a control, β-galactosidase was co-transfected with HD1955. In the control transfections, 1-2% of cells expressing HD1955-128 formed aggregates in the absence of tamoxifen, similar to HD1955-128 expressed alone. However, when HD1955-128 was co-expressed with HIP-1, an average of 14% of huntingtin-expressing cells contained aggregates with no tamoxifen treatment. Double-labeling demonstrated that the majority of the cells containing aggregates also expressed HIP-1, directly implicating HIP-1 in the increase in aggregation. Therefore, these results indicate that HIP-1 provides sufficient stress on the huntingtin-expressing cells to form aggregates, to the extent that tamoxifen is no longer necessary.

**EXAMPLE 15**

We next designed a series of experiments to identify a region of HIP-1 sufficient for inducing aggregate formation of HD1955-128. As described above, HIP-1 contains a domain with high homology to the death effector domains (DED) present in many apoptosis-related proteins. The DED domain of HIP-1 was ligated in-frame to HD1955-128, 3' from the caspase-3 cleavage site. Transfection of the resulting fusion protein with the DED ligated in the sense orientation (HD1955-128-DEDsense) resulted in a large number (30-50%) of cells containing aggregates, without tamoxifen incubation. In contrast, expression of a huntingtin-DED fusion protein with DED in the antisense orientation (HD1955-128-DEDantisense) did not have more aggregates than the HD1955-128 no tamoxifen control. Therefore, the DED domain of HIP-1 is sufficient to stress the cells, causing aggregate formation.
EXAMPLE 16

To directly assess the effect of HIP-1 expression on cell viability, mitochondrial function tests were performed on 293T cells transfected with HIP-1. The assessment of mitochondrial function, using the MTT assay (Carmichael et al., Cancer Res. 47: 936-942 (1987); Vistica et al., Cancer Res. 51: 2515-2520 (1991)), is a standard method to measure cell viability. The MTT assay quantitates the formation of a coloured substrate (formazan), with the mitochondria of viable cells forming more substrate than non-viable cells. Since decreased mitochondrial activity is an early consequence of many cellular toxins, the MTT assay provides an early indicator of cell damage.

For cell viability assays, HEK 293T cells were seeded at a density of 5 x 10^4 cells into 96-well plates and transfected with 0.1 ug or 0.08 ug HIP-1 or 0.1 ug of the control construct lacZ using the calcium phosphate method described above. At 24-36 hours post-transfection tamoxifen-treated cells were incubated for 2 hours in a 1:10 dilution of WST-1 reagent (Boehringer Mannheim) and release of formazan from mitochondria was quantified at 450 nm using an ELISA plate reader (Dynatech Laboratories) (Carmichael et al., 1987; Mosmann, J. Immunol. Meth 65: 55-63 (1983)). One way ANOVA and Newman-Keuls test were used for statistical analysis. The transfection efficiency, measured by β-galactosidase staining and immunofluorescence, was approximately 50%.

We have previously demonstrated that expression of mutant huntingtin results in increased susceptibility to an apoptotic stress induced by sub-lethal doses of tamoxifen in transfected 293T cells (Martindale et al., 1998). A similar assay was used to test the consequence of HIP-1 expression. With 0.1 ug transfected HIP-1 DNA, after 24 hr expression, HIP-1 resulted in increased cell death in response to tamoxifen, compared with the tamoxifen-treated β-galactosidase control (p<0.01, n=4). Reducing the amount of transfected HIP-1 DNA to 0.08 ug also resulted in increased cell death compared with control (p<0.01, n=4), indicating the high potency of HIP-1 (Fig. 8). Furthermore, increased cell death in cells transfected with HIP-1 was observed in the absence of apoptotic stress at 48 hrs post-transfection, but was so severe that is could not be accurately quantitated. Thus, an earlier time point (24 hr) had to be used for better reproducibility, using an apoptotic stress to unmask the phenotype.
In order to model a pathogenic interaction of HIP-1 and huntingtin in the HEK 293 mammalian cell system, HIP-1 was transfected into cell lines stably expressing huntingtin. Two cell lines were chosen for the initial studies, one line expressed the truncated HD1955 construct with 15 glutamines, and the second expressed the HD1955 with 128 repeats. Western blotting indicated that the cell lines expressed huntingtin at similar levels. To assess whether HIP-1 is toxic in the presence of mutant huntingtin, 0.1 ug HIP-1 DNA was transfected into the HD1955-128 cell line. Transfection of HIP-1 into the HD1955-15 cell line was used as the wild-type huntingtin control, and transfection of LacZ into both cell lines was the control for transfection-related toxicity (Figs 9A and 9B). MTT toxicity assays showed that HIP-1 in the presence of mutant huntingtin (HD1955-128) was significantly more toxic than HIP-1 with wild-type huntingtin (HD1955-15), p<0.001, n=4 (Fig. 9C). This toxicity was observed at 24 hr and 36 hr post-transfection. No tamoxifen was needed to unmask the phenotype, suggesting that the combined cell stress of HIP-1 with truncated huntingtin was sufficient to reduce cell viability over control.
CLAIMS

1. A polypeptide comprising the sequence given by Seq. ID. No. 5.

2. A cDNA molecule comprising the sequence given by Seq. ID No. 6.

3. A polypeptide comprising the sequence given by Seq. ID No. 7.

4. A method for ameliorating the effects of Huntington’s disease in a patient expressing a HIP-apoptosis modulating protein, comprising the step of administering the patient a therapeutic composition which reduces the activity of the HIP-apoptosis modulating protein.

5. A method according to claim 4, wherein the composition comprises a material which binds to HIP-apoptosis modulating protein.

6. The method according to claim 4, wherein the composition comprises an expression vector encoding huntingtin having a normal number of repeats.

7. An expression vector for expression of a gene in a mammalian host comprising a region encoding an HD-interacting polypeptide.

8. The expression vector according to claim 7, wherein the HD-interacting polypeptide is an HIP-apoptosis modulating protein.

9. The expression vector according to claim 8, wherein the HIP-apoptosis modulating protein has a sequence which includes the amino acid sequences given by SEQ ID Nos. 2, 4, 5 or 7.
10. The expression vector of claim 7, wherein the HD-interacting polypeptide interacts differently with expanded Huntingtin than with Huntingtin having a CAG repeat region containing 15 to 35 repeats.

11. The expression vector according to claims of claims 7-10, further comprising a region encoding Huntingtin having a polyglutamine tract of 35 or fewer.

12. A method for inducing apoptotic death in cells, comprising the step of introducing into the cells an expression vector encoding at least the death effector domain of a HIP-apoptosis modulating protein whereby the death effector domain is expressed by the cells.

13. The method of claim 12, wherein the expression vector encodes the amino acid sequence given by Seq. ID. No. 2.

14. The method of claim 12, wherein the expression vector encodes the amino acid sequence given by Seq. ID. No. 4.

15. A method for screening a composition for the ability to inhibit apoptosis induced by an HIP-apoptosis modulating protein, comprising simultaneously exposing a population of cells to the composition and an HIP-apoptosis modulating protein and measuring the extent of cell death.
Fig 2

HIP1 Clones: Nucleotide Alignment

HIP1

ATG
1
245

STOP
2987

4796

HIP1a
(3.2kb)

876

3058

STOP

53%

mHIP1
(2.3kb)

ATG
726

STOP
3015

85%

mHIP1a
(4.0 kb)

195

12

2703

STOP

60%
Fig 3
HIP1 Clones: Protein Alignment

HIP1

HIP1a
(653aa)

mHIP1a
(1068aa)

mHIP1
(691aa)

58%
61%
90%
Fig 4

>Usurpin A
SDEVIRQVEAALDTDEKMLMLFCRVAIDVPPVNVADLLDLRERGKSVCDLAEYLVHRPDLLKRLK

>Usurpin B
YRVLMAHIGEDLDSSSLIFLMLKDYKGRKISIKSHFLLVLHELKQLNLVAPDQIADLEKCLKNEHILIKLKTQK

>Casp-8 A
FPRNLQDIELELDLSKELSDYTPQRKOPKDALFQRLOKRLKMEESLTLSFLKELFRDRLODLYIN

>Casp-8 B
YRMLYQSIKSEVSREEKSFSKFLQEISESKCLODDMMNDLQFITEMKEVRGEKILDILRKVCAQINSLLKIND

>Casp-10 A
FRHKLTLTIDSNLGVDONNFKLFLGCLFVNMKLEKSSSSADVFEHLLLRHAEDDLSEEOPFALAYLYITQRLKQLQHLNC

>Casp-10 B
FRNLYELSGIDSENLKDHIFLKLKCLKFKTKMTLESLSDLAFLKQQMDIDEDENLTCLEDLCTPVKLLRNIK

>PADD
FLVLLHSVSSSLSSSETELKFLGLRQKMKLERQSVSGLP3MHEQNLDEPQHTELELHLLASLRLRLDDLRBVDD

>MC159 A
SLPFLKMLLEELSDHEDSLLFLGHLDAAPGCTTVQALTCSLSQQKLTTLAALVEMVLQRWMDDLKSRPG

>MC159 B
YHLKMCVGVGGELOSSIRAHLRALFACNINLPSLYSTSESSRPTVLELAELEVGLVSPSSVSVLADMLRTIIRLDLCQQLVE

>E8
FRCLMALVNDLDSDKVEEVEHYFLCAFRLESPHKSFLRASLLELOLGGDKLTFLRHLLTTTGAGKLVLNNY

>KS orf13A
TYEVLCEVARKLGTDORRVEVLFLLNVFLPQPTLALQIGALRAKKEEGRLTFFLAELPRAGRRORLLHDLH

>KS orf13B
YQTVLIVHVDGELCADYRSLIFLSKDTIGSRTPQTOFHVCMNLDDLGLGPTDUALMSLMRSLRVDLQRVQVT

>HiFi1
SELEAALAEQOHRLQQADDCEIFRAEDELDRRQREDTEKAQRLSEIZEERKAQANEQYRSKLLKEYSELVQNHADLLRKN

>HiFi1a
GELEEQKQKQKALVDNQARHAELAQRALAQAQLRESRSQGLREAEKASATEARYNKLKHEHSLVIVIHALLRKNAD

>HiFi1a
NGLEAELEEQKQKQKALVDNERAELAQRALAQAQLRESRSQGLREAEKASATEARYSKLKHEHSLINTHAELLKN

>HiFi1
SELEAALAEQOHRLQQADDCEIFRAEDELDRRQREDTEKAQRLSIEERKAQANEQYRSKLLKEYSELVQNHADLLRKN

>HiFi1a
GELEEQKQKQKALVDNQARHAELAQRALAQAQLRESRSQGLREAEKASATEARYNKLKHEHSLVIVIHALLRKNAD

>HiFi1a
NGLEAELEEQKQKQKALVDNERAELAQRALAQAQLRESRSQGLREAEKASATEARYSKLKHEHSLINTHAELLKN

>HiFi1
SELEAALAEQOHRLQQADDCEIFRAEDELDRRQREDTEKAQRLSIEERKAQANEQYRSKLLKEYSELVQNHADLLRKN

>HiFi1a
GELEEQKQKQKALVDNQARHAELAQRALAQAQLRESRSQGLREAEKASATEARYNKLKHEHSLVIVIHALLRKNAD

>HiFi1a
NGLEAELEEQKQKQKALVDNERAELAQRALAQAQLRESRSQGLREAEKASATEARYSKLKHEHSLINTHAELLKN

Fig 7
Mouse ESTs

HIP1
ATG 245

STOP 2987

4796

1880 2259
AA110840 (399bp) 58%

2750 2915 3163
W82687 (420bp) 66%

2475 2692 2859
AA388714 (404bp) 83%

2323 2763 2832
AA138903 (509bp) 88%
Hip1 increases the susceptibility to cell stress.

**HIP1 TOXICITY**

<table>
<thead>
<tr>
<th>Construct</th>
<th>Absorbance</th>
</tr>
</thead>
<tbody>
<tr>
<td>pCI Neo-0.1ug</td>
<td>0.050</td>
</tr>
<tr>
<td>RSV LacZ-0.1ug</td>
<td>0.050</td>
</tr>
<tr>
<td>HIP1-0.1ug</td>
<td>*</td>
</tr>
<tr>
<td>RSV LacZ-0.08ug</td>
<td>*</td>
</tr>
<tr>
<td>HIP1-0.08ug</td>
<td>*</td>
</tr>
</tbody>
</table>

*Fig 8*
HIP1 is toxic in the presence of huntingtin.

HIP1 transfected into HD1955-15 stable cell line
36 hr post-transfection

Absorbance

0.15

0.10

0.05

0.00

HIP1

LacZ

Vector

Mock

Transfected constructs

Fig 9A
HIP-1 is toxic in the presence of huntingtin

HIP1 transfected into HD1955-128 stable cell line
36 hr post-transfection

![Graph showing absorbance levels for transfected constructs: HIP1, LacZ, Vector, Mock.](image)

**Fig 9B**
(1) GENERAL INFORMATION:
   (i) APPLICANT: Kalchman, Michael
       Hayden, Michael R.
       Hackam, Abigail
       Chopra, Vikramjit Singh
       Nicholson, Donald W.
       Vallaincourt, John P.
       Rasper, Dita M.
   (ii) TITLE OF INVENTION: Apoptosis Modulators That Interact with the
       Huntington’s Disease Gene
   (iii) NUMBER OF SEQUENCES: 44
   (iv) CORRESPONDENCE ADDRESS:
       (A) ADDRESSEE: Oppedahl & Larson
       (B) STREET: PO Box 5270
       (C) CITY: Frisco
       (D) STATE: CO
       (E) COUNTRY: USA
       (F) ZIP: 80443-5270
   (v) COMPUTER READABLE FORM:
       (A) MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Kb storage
       (B) COMPUTER: IBM Compatible
       (C) OPERATING SYSTEM: MS DOS 5.0
       (D) SOFTWARE: WordPerfect
   (vi) CURRENT APPLICATION DATA:
       (A) APPLICATION NUMBER:
       (B) FILING DATE:
       (C) CLASSIFICATION:
   (viii) ATTORNEY/AGENT INFORMATION:
       (A) NAME: Larson, Marina T.
       (B) REGISTRATION NUMBER: 32038
       (C) REFERENCE/DOCKET NUMBER: UBC.P-013US2
   (ix) TELECOMMUNICATION INFORMATION:
       (A) TELEPHONE: (970) 668-2050
       (B) TELEX: (970) 668-2052

(2) INFORMATION FOR SEQ ID NO: 1:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 1164
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: cDNA
   (iii) HYPOTHETICAL: no
   (iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(ix) FEATURE: cDNA for Huntingtin-interacting protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACAGCTGACA CCCTGCAAGG CCACCGGAGG CGCTTTCACTGG AGCAGTTTAC 50
AAAGTGGAAA GATCTGTTCT ACCGCCTCAG CAACCTGCGA TACTTCAAGC 100
GGGTCAATTC GATCCACCGG CTGCCGTGAGA ACCCGACCAA CTTCCTGCGA 150
GCCCTCAGCC TTGTCAGAAA TATCAGCCCT GTGGTGTCGA TCCCTGCAAG 200
GCCCTCATCC CCCGCACAGG AGCCAGTCTC AGAGAAGGAT GACCTCAGTG 250
ACATGGATGC CTCTGACGAG AATTATTTTG ACAACAGATT TGATGACNTC 300
TTTTGGCAAT TTATCCACAG TAGTCCCTTC AATTTCAACA GTCIAAAATGG 350
TGTGAACCAA GATGAGAAAG ACCACTTATA TGAGCGACTA TACAGAGAGA 400
TCAGTGGATT GAAGGCACAG CTGAGAACA TGAAGACTGA GAGCCACGGG 450
GTTGGTCTGC AGCTGAAAGG CAACGCTCAGC GAGCTGGAAG CAGATCTGCG 500
CGAGGACAGG CACCTGCGGC AGAGCCGGGC CGACGCAGGG TAACTCCTGC 550
GGCGGACTG GAGGAGGCCT GCNGGCCACG GGGAGGACAC CGAGAGAGCT 600
CAGGGAGGCC TGCTGAGAT AGAAGGAAGA GCTCAAGCCAA ATGAAACAGC 650
ATATAGCAAG CTAAAGGGAG AGTACAGCGA GCTGGTTCAG AACCACCGTG 700
ACCTGCTCCG GAAAGTAACG GATGTGACCA CAGCGGCTAG CAGTCAGGCA 750
CAAGCCAGGC TAGATTTGGAA ACGAGGAAA AAAAGCTGCTT AGGATCTGTT 800
GGAGGCGATC AGTGACCAAG GGCCAGGGA CACCTCAGAA CAGCTGGAAG 850
TTCTAGAGAG CTCTGGACAG GAACTGCGCA CAGAGCAAGG GGAGGTCCAG 900
TTTCTCGAG GCAGCCTGGA AACTTCTGGC GACTCAAGAG CAAACTGGGC 950
AGCCGAGTTC GCCGCAGCTAG AGAAGGAGCG GAGCGACCTG GTAGTGCGGC 1000
CAGCTCATAG GGGAGGGAA TTAGCCTCTC TCTCGAGAA ACGATTGAGG 1050
ACTCACTCTA AACTGGGAC CATGAGGAAA TCTATGTTCCAG ACTTGAGCAA 1100
AGACCAAAGA AAAATGCTTC TGTTGGGAGTC GAGGAGGCTG CAGGAGCGAGC 1150
TGATACAGA CGCG 1164

(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 386
(B) TYPE: protein
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(ix) FEATURE: Huntingtin-interacting protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Thr Ala Asp Thr Leu Gln Gly His Arg Asp Arg Phe Met Glu Gln 1 5 10 15 20
Phe Thr Lys Leu Lys Asp Leu Phe Tyr Arg Ser Ser Asn Leu Gln 25
Tyr Phe Lys Arg Val Ile Gln Ile Pro Gln Leu Pro Glu Asn Pro 30
<table>
<thead>
<tr>
<th></th>
<th>35</th>
<th>40</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pro Asn Phe Leu Arg Ala Ser Ala Leu Ser Glu His Ile Ser Pro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>Val Val Val Ile Pro Ala Glu Ala Ser Ser Pro Asp Ser Glu Pro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>Val Leu Glu Lys Asp Asp Leu Met Asp Met Asp Ala Ser Gln Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>85</td>
<td>90</td>
</tr>
<tr>
<td>Asn Leu Phe Asp Asn Lys Phe Asp Asp Phe Gly Ser Ser Ser Ser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>95</td>
<td>100</td>
<td>105</td>
</tr>
<tr>
<td>Ser Asp Pro Phe Asn Phe Asn Ser Gln Asn Gly Val Asn Lys Asp</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>110</td>
<td>115</td>
<td>120</td>
</tr>
<tr>
<td>Glu Lys Asp His Leu Ile Glu Arg Leu Tyr Arg Glu Ile Ser Gly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>130</td>
<td>135</td>
</tr>
<tr>
<td>Leu Lys Ala Gln Leu Glu Asn Met Lys Thr Glu Ser Gln Arg Val</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>140</td>
<td>145</td>
<td>150</td>
</tr>
<tr>
<td>Val Leu Gln Leu Lys Gly His Val Ser Glu Leu Glu Ala Asp Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>155</td>
<td>160</td>
<td>165</td>
</tr>
<tr>
<td>Ala Glu Gln Gln His Leu Arg Gln Gln Ala Ala Asp Asp Cys Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>170</td>
<td>175</td>
<td>180</td>
</tr>
<tr>
<td>Phe Leu Arg Ala Glu Leu Asp Glu Leu Arg Gln Arg Glu Asp Thr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>185</td>
<td>190</td>
<td>195</td>
</tr>
<tr>
<td>Glu Lys Ala Gln Arg Ser Leu Ser Glu Ile Glu Arg Lys Ala Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>205</td>
<td>210</td>
</tr>
<tr>
<td>Ala Asn Glu Gln Arg Tyr Ser Lys Leu Lys Glu Lys Tyr Ser Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>215</td>
<td>220</td>
<td>225</td>
</tr>
<tr>
<td>Leu Val Gln Asn His Ala Asp Leu Leu Arg Lys Asn Ala Glu Val</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>230</td>
<td>235</td>
<td>240</td>
</tr>
<tr>
<td>Thr Lys Gln Val Ser Met Ala Arg Gln Ala Gln Val Asp Leu Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>245</td>
<td>250</td>
<td>255</td>
</tr>
<tr>
<td>Arg Glu Lys Lys Glu Leu Glu Asp Ser Leu Glu Arg Ile Ser Asp</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>260</td>
<td>265</td>
<td>270</td>
</tr>
<tr>
<td>Gln Gly Gln Arg Lys Thr Gln Glu Gln Leu Glu Val Leu Glu Ser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>275</td>
<td>280</td>
<td>285</td>
</tr>
<tr>
<td>Leu Lys Gln Glu Leu Gly Thr Ser Gln Arg Glu Leu Gln Val Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4796
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii)MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: no
(iv) ANT-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(ix) FEATURE: cDNA for Huntingtin-interacting protein
(xi)SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CAGTGTACGG TTGATCATAT AAGCCCGCGG GCGGGGATTG GTTTATATAT 50
CGCAAATGA TGTAGGGGG GGGGATGGN CAGAGAATTC GCTTCATTAG 100
GCCATTATAA GCAGAAAGGG TTTCAAGGAA AAAACCAG AAAGTCATA 150
TTGCAACCCAC CATGAGAAGG GGGCAACAGA CCTTNTGTGN TGTNTACAC 200
CGGCTGCTTC TGTTTTAGCA AACAGTGTTT TTGTTGGAAG TGGTGGCATG 250
TTGTTCCACAA ANTCTCCGGG GATGGACACC GAAACTCTCTT GAAGGACTTT 300
GTGAGATACA GAAATGAAATT GAGTGACATG AGGAGATGAT GGGCCACCT 350
GAGCGAGGGG TATGGGCAAG TGTGACAGAC ATCACCTGAA CTGCTAAGAA 400
CCAGATGTGA GTACCACCAC AAAAAATCCA GGTCCAGG CAACCTGCA 450
ATGAGTGACC GCCAGCTGGA CAGGCTGGA GAAATGACGC TGAACAAGCT 500
TTTCCAGTAA ACAGTGGAAGA TGTTTGACCTA CCTGGAGTTG GAACTCAACC 550
TCTTCCCCCA AGTATTACAC TCCCTGGACA TGTCCCCCTC TGGTTCGGTG 600
ACGGCAGCCA GGGAGTGCCG CTCGCCCAGG CTGATCCACG TCAATCTGGA 650
CTCGCAGCCAC CTATTATGACT ACACGTGCAAC GCTTCTCTCC AAACCTCCACT 700
CCTGCTCCAC AGCTGACACC CTGCAAGGCC ACCGGGACCAG TGCTCATGGAG 750
<table>
<thead>
<tr>
<th>Sequence</th>
<th>Description</th>
<th>Accession</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAGTTTACAA AGTTGAAGA TCTGTTCATC GCCTCCAGCA ACCTGCAGTA</td>
<td>800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTTCAAGCGG CTCATTCGGA TCCCCAGCTT GCCTGAAAGAC CCACCCAACT</td>
<td>850</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCTGCGGAGG CTCAGCCTTGG TCAAGACATAT TCAAGGCTCT TGTGGTGATC</td>
<td>900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTGGCAGGAG CCTCTATCCCC ATGGCCAGAG AATATATTTGA AAAAAAGGAC</td>
<td>950</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTCAGGACGG CTCATCTCCAC TCAAGGTCAGG CAGGCAGAGA AGAGGTATGA</td>
<td>1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATGGCACTTTC TGCCAGCTTA TCTGAGCAGT ATCCCTCTCA TTTCAACAGT</td>
<td>1050</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAAAAGGTTG TGAAGAAAGG TAAAGGGGAC CATTAAATTT CAGGGTAAAT</td>
<td>1100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAGAGAGATG AGTGAAATGG AGGCACAGCT AGAAACATGT AAGACTGAGA</td>
<td>1150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGCCGGGAAG TCTGCTCGAA CAGTAGGAGCC AGCTCAGCCA GCTGGAAAGA</td>
<td>1200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCTTAGCGCC GCAGCCAGCA CTGCGGAGCC CAGGGCGAGC ACAGCTGGTA</td>
<td>1250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATCCAGTCCG GCAGAAGCTG AGCAGCTCAC GAGGCGCAGG GAGGACACCC</td>
<td>1300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGAAGGCTCA GCGGAAGCTG TCTGAGTAGA AAGGGAAGAC TCAAGCCAAT</td>
<td>1350</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAACAGCAGT ATACCAAGCT AAGAGAAGAG TACAGGCGAG TCGTTCAAGG</td>
<td>1400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCAGAGTCAG CTGCTCGGGA AGAATGCAAG GGTGGCAACA CAGGGTCCTA</td>
<td>1450</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGCCAGACGA AGCGCCAGTA GATTGGGACA GAGAGAAAG AAGACTGCGG</td>
<td>1500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATTCGCTTCG AGGAGCAGCC TCTGAGGGCC CAGCGGAGGA ATCAAGAAC</td>
<td>1550</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCTGGAGTTA CTAGAAGATG TGAAGCCAGG ACTTGGCCACA AGCCCAAGGG</td>
<td>1600</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGTCTGCAGGT TCTGGACTCA AGGCTTGAAGA CTTGCTCCCA GTCTGAAAGA</td>
<td>1650</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACTGGCGCA CCGAGTTGGC GAGAATAGAG AAGGACGGGC AAGCTCGTGTG</td>
<td>1700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAGTGTTCCGA GCTCATAGTG AGGAGAATT AATCTGCTCTT CAGAAAGAAC</td>
<td>1750</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGCCAGACAC TCGCTCAGAA TCTGCGAGCA CAGAGAATAT TATGGTGCCG</td>
<td>1800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCTGCGAACAG CACGAGCAAA AATGACTTGT TGAGGCTCCA GAGGCTGTCG</td>
<td>1850</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGAGCAAGTG ATACAGAAGC CCCTGAGGCA GCTTTGAGAA CCTCTCCTCA</td>
<td>1900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TACAGCTGCAG GTGGCTTCTCA GATCAGCTCC TCTCCAGCTC CAGATCCATT</td>
<td>1950</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TCAGCTCGCA TCGAGCAAGA GAGAAGAAGC TGGAGCAGCT GTAAGGACTG</td>
<td>2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CACAGAGAAG ATACAGTGGAC TTCTCATATT CATACACCTG CTGGCCCACC</td>
<td>2050</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGACGGACCA GCAGCCAGTA CATTGGGCTA CACACCTGCT CACAGCCCAA</td>
<td>2100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCTGAGCTTG CCGACTCAGT GACGAGGCCG TGTAAGACGT ATGGGAGGGA</td>
<td>2150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACCTCTGCC TACCTGCGCT TCCCCGAGAG AAGGGAAGAC CTTGAGAATG</td>
<td>2200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCGACAGCAC AGGCATGGGA AACTGGCTCA GCAGATCAAA GGCCATCGGC</td>
<td>2250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAGGAGCTCC TGCCGGAGGG ACTGGCAATC AAGCAGGAGG AGCTGGGGGA</td>
<td>2300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCTGGTGAGA AAGGAGATGG CGCGACTCTT AGCTGCTATT GAACATGTCG</td>
<td>2350</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGGGCAAGAT AGAGGAGATG TCAAGCAAGA CCCCCGAGA GACACAGAGA</td>
<td>2400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTCAAAATGG AGGTAAGATA AGGAGACTCT CTGTTGCTGA CAGGCCCTAT</td>
<td>2450</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCAAGCTATT CAGGTCGCTCA TCTGGGCTCT TAAAGACCTC CAGAGGAGA</td>
<td>2500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTGGAGGAGG CAGGGCAGCTC AGACATCCC CTAAGAGATT ATTTACGAGA</td>
<td>2550</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACCTCTGAGT GGACAGAAGG ACTTATCTCA GCCGCCAGAAG CTTGGGTGGT</td>
<td>2600</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGAGCAGACT GTCCAGTTTAG ATGCCAGTGA TCTGGTGCTA CAAAGCAGAG</td>
<td>2650</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGAAATTAGT GGACACTTATGC TCTGGTGTCTC ATGAGAAAAA GTCAGGAGAA</td>
<td>2700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCCCAGCTTG TGCGCTGATC GAAGTGGAAC GCTGATAAGG ACAGCCCAA</td>
<td>2750</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCTAGCCAGG CTCAGGGGAG CTTGCTGGGG AGTGAAAGCC GACACCTGGC</td>
<td>2800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGAGTGTTGC ATCAACCATG TCCGGCAATA CACAGATCGA AGAGACAGAC</td>
<td>2850</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACAGTCAGT GCTCCAGCAT GAGCTGAGCA CAGATCCAAC GCGAAGGAGA</td>
<td>2900</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GGATTTCCAG GTTATGGTGC TAGAGCTGTA ATGAGATAAT CAGAGAGGAG</td>
<td>2950</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCTAAAAACT CGGAGAGCAGT CGGAAAAAGC ACTAAGCACGT TGCTGGTGTT</td>
<td>3000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCTGGAGGCT CCAGGAAGAG AACAGAGGCA TCTCAGCACT CACTGGAAGA</td>
<td>3050</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGTGGAACCC GAAAAGAAG ATAGGCAGAC CACAGCAACA TATTGCCAGT</td>
<td>3100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAAACCTCTTG CTACTGTATC CTGGTGTGTT ATTTCCCAGG CCCAGGCGCA</td>
<td>3150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AATCCGTGGA GTCCAGCGAG CAGAGCACC ACTGCACATTA CCACTGGCGC</td>
<td>3200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGGAGCTGCA TGAGACTCAG TCAAGATGCC TCCATACGCA CACCAATTC</td>
<td>3250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTTTGGACCC ATGGTCATCT CTGTTCATT TCCGCTCCAC TAGTGAGCAT</td>
<td>3300</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CCAGGCTGGCC CAGTGCTGCC CATGAGCAAG CCTAGGTACG AAGAGGGTG 3350
GTGGGGGGCGA GGCGCACTCA ACAAGAGGGA CCAACATCCA GTGGTGCTGA 3400
CTATTTGGGC CCCAACAACA TGGTATCCT TAATAGAGGA GTGCTGTTGTT 3450
GTPTTGTGAC GCATTTGGAA ATGAGTAGTC ATGTTGGCCTT TTTTCTTGT 3500
TTCTTGTCA TCTTTACTTG TTACATATTG GCACAAACTT GTGACCATCA 3550
GAGGGCTGAT GGATTCAAAA CAGGAGACTT ACCCATGAGAT CTGCAAGTGC 3600
AGAGAGGCGA CAGGGAGTGC CGTGCTTGTA AGCGCAACAG ATTCCCTCCTC 3650
CTCTTTGGGC AGGTCCATGG ATTTACACTG ATCTTTATGG TGGTGGGGTG 3700
GTGGTTTTGG TTTTGTTTTT TTTTCTTTAG ATTTACTTGC ATAGCCACTT 3750
CTTCCCAAGG GCACACCCCT GGGCTGAGTT TCCAGGCTCC CCCCAACTCGT 3800
GTGAGCTCCA GCGATGGTGTC TGCCACGGCC TCTCGTGACT CTATCTCCGC 3850
CTCCACACTG ACCAGTGCTT GGCACACCCA GCCATGGCTC CAGGTCAGG 3900
CGGAGCTGCT GAGTGACAGC TTCTCTCAAA AGAGCAAGAG AGGATGAGTG 3950
CTCTTCTCCT CTAAAGCTGA ATCCGCGGGG AAGAGCTCGT TCCGCTCTTA 4000
CAAGGGGAGA TACAAACGGGA AGAGGGACAA AGGCTTCCAC ACAGCCGCTG 4050
TCCGCTGAGC AGGCTCAAAG CAATGATGAC ATCTGGTCCAT AGAGCTGGTG 4100
AGATCAACAA CACTACTTCC CTGCGGAGAT GACATGCTCC TGAATGGCTC 4150
CTGTCAGGCC GGCGCTCTCC CTGGGCGCCG AGAGGGAGTG TGGAGTGATG 4200
TCCAACAATC TTTCTGAGTA GCTGTCACGG GCGACTCCCT TGAATAGGAA 4250
GACAGTCTCA CTTCTCTCCGC AATGACAAAA CCCGGAGAGT CAGATGCAAT 4300
TGCCTCCTAC ATGGGAAGAC CTAATACTTT GTTTCTTACC TCTGATTTTT 4350
ATTACTAAAAC TCCCTTTAACG AGGAAGAGCC TACAAAGAGA TGCTTGGAGC 4400
AATCAGAACT TCAGGTGTGA CCTAGCCACA GCTCATCTTT CTGCGCGGCT 4450
ACATCAAGCT TCAAGAATCA GAGAAGACCC AAGTGCTGTA ACTGTTACTG 4500
ACTGGAATCC CAAAGCAAGG AGATCATTGG GAGCTCTTGG TCGAAGAAA 4550
AGTGAAGGAG ACAGGCCAG CGGCTCAAAC TTCTTCTAGC CACATGCCCC 4600
AGGGCTCTGC TGCCCTGGTG ACAGAGTGG GACAGGAGCC AGCATGACAG 4650
CTTGCAGGGA ATGGCAGGCC CAACAGCAGT TCTACTTCTTC TAGATGGACC 4700
CCAGCATTTA AGTGAGCTTC TGACTTGAGG AAAACAGCGT CTTCTTCTTT 4750
TATCTATAGC AACTCATTTG TGTTAGGATT CAAGCCTTTC GGAATT 4796

(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 924
   (B) TYPE: protein
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
   (ix) FEATURE: Huntington-interacting protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Ser Arg Met Thr Gly His Leu Ser Glu Gly Tyr Gly Gln Leu
1      5       10       15

Cys Ser Ile Tyr Leu Lys Leu Leu Arg Thr Lys Met Glu Tyr His
20     25       30

6
Thr Lys Asn Pro Arg Phe Pro Gly Asn Leu Gln Met Ser Asp Arg
35  40   45

Gln Leu Asp Glu Ala Gly Glu Ser Asp Val Asn Asn Phe Phe Gln
50   55   60

Leu Thr Val Glu Met Phe Asp Tyr Leu Glu Cys Glu Leu Asn Leu
65   70   75

Phe Gln Thr Val Phe Asn Ser Leu Asp Met Ser Arg Ser Val Ser
80  85   90

Val Thr Ala Ala Gly Gln Cys Arg Leu Ala Pro Leu Ile Gln Val
95 100  105

Ile Leu Asp Cys Ser His Leu Tyr Asp Tyr Thr Val Lys Leu Leu
110 115  120

Phe Lys Leu His Ser Cys Leu Pro Ala Asp Thr Leu Gln Gly His
125 130  135

Arg Asp Arg Phe Met Glu Gln Phe Thr Lys Leu Lys Asp Leu Phe
140 145  150

Tyr Arg Ser Ser Asn Leu Gln Tyr Phe Lys Arg Leu Ile Gln Ile
155 160  165

Pro Gln Leu Pro Glu Asn Pro Pro Asn Phe Leu Arg Ala Ser Ala
170 175  180

Leu Ser Glu His Ile Ser Pro Val Val Val Ile Pro Ala Glu Ala
185 190  195

Ser Ser Pro Asp Ser Glu Pro Val Leu Glu Lys Asp Asp Leu Met
200 205  210

Asp Met Asp Ala Ser Gln Gln Asn Leu Phe Asp Asn Lys Phe Asp
215 220  225

Asp Ile Phe Gly Ser Ser Phe Ser Ser Asp Pro Phe Asn Phe Asn
230 235  240

Ser Gln Asn Gly Val Asn Lys Asp Glu Lys Asp His Leu Ile Glu
245 250  255

Arg Leu Tyr Arg Glu Ile Ser Gly Leu Lys Ala Gln Leu Glu Asn
260 265  270

Met Lys Thr Glu Ser Gln Arg Val Val Leu Gln Leu Lys Gly His
275 280  285
Val Ser Glu Leu Glu Ala Asp Leu Ala Glu Gln Gln His Leu Arg
--- 290 295 300 ---
Gln Gln Ala Ala Asp Asp Cys Glu Phe Leu Arg Ala Glu Leu Asp
--- 305 310 --- 315 ---
Glu Leu Arg Arg Gln Arg Glu Asp Thr Glu Lys Ala Gln Arg Ser
--- 320 325 330 ---
Leu Ser Glu Ile Glu Arg Lys Ala Gln Ala Asn Glu Gln Arg Tyr
--- 335 340 345 ---
Ser Lys Leu Lys Glu Lys Tyr Ser Glu Leu Val Gln Asn His Ala
--- 350 355 360 ---
Asp Leu Leu Arg Lys Asn Ala Glu Val Thr Lys Gln Val Ser Met
--- 365 370 375 ---
Ala Arg Gln Ala Gln Val Asp Leu Glu Arg Glu Lys Lys Glu Leu
--- 380 385 390 ---
Glu Asp Ser Leu Glu Arg Ile Ser Asp Gln Gly Gln Arg Lys Thr
--- 395 400 405 ---
Gln Glu Gln Leu Glu Val Leu Glu Ser Leu Lys Gln Glu Leu Gly
--- 410 415 420 ---
Thr Ser Gln Arg Glu Leu Gln Val Leu Gln Gly Ser Leu Glu Thr
--- 425 430 435 ---
Ser Ala Gln Ser Glu Ala Asn Trp Ala Ala Glu Phe Ala Glu Leu
--- 440 445 450 ---
Glu Lys Glu Arg Asp Ser Leu Val Ser Gly Ala Ala His Arg Glu
--- 455 460 465 ---
Glu Glu Leu Ser Ala Leu Arg Lys Glu Leu Gln Asp Thr Gln Leu
--- 470 475 480 ---
Lys Leu Ala Ser Thr Glu Glu Ser Met Cys Gln Leu Ala Lys Asp
--- 485 490 495 ---
Gln Arg Lys Met Leu Leu Val Gly Ser Arg Lys Ala Ala Glu Gln
--- 500 505 510 ---
Val Ile Gln Asp Ala Leu Asn Gln Leu Glu Glu Pro Pro Leu Ile
--- 515 520 525 ---
Ser Cys Ala Gly Ser Ala Asp His Leu Leu Ser Thr Val Thr Ser
--- 530 535 540 ---
<table>
<thead>
<tr>
<th>WO 99/60986</th>
<th>PCT/US99/11743</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ile Ser Ser Cys Ile Glu Gln Leu Glu Lys Ser Trp Ser Gln Tyr</td>
<td></td>
</tr>
<tr>
<td>545</td>
<td>550</td>
</tr>
<tr>
<td>Leu Ala Cys Pro Glu Asp Ile Ser Gly Leu Leu His Ser Ile Thr</td>
<td></td>
</tr>
<tr>
<td>560</td>
<td>565</td>
</tr>
<tr>
<td>Leu Leu Ala His Leu Thr Ser Asp Ala Ile Ala His Gly Ala Thr</td>
<td></td>
</tr>
<tr>
<td>575</td>
<td>580</td>
</tr>
<tr>
<td>Thr Cys Leu Arg Ala Pro Pro Glu Pro Ala Asp Ser Leu Thr Glu</td>
<td></td>
</tr>
<tr>
<td>590</td>
<td>595</td>
</tr>
<tr>
<td>Ala Cys Lys Gln Tyr Gly Arg Glu Thr Leu Ala Tyr Leu Ala Ser</td>
<td></td>
</tr>
<tr>
<td>605</td>
<td>610</td>
</tr>
<tr>
<td>Leu Glu Glu Glu Gly Ser Leu Glu Asn Ala Asp Ser Thr Ala Met</td>
<td></td>
</tr>
<tr>
<td>620</td>
<td>625</td>
</tr>
<tr>
<td>Arg Asn Cys Leu Ser Lys Ile Lys Ala Ile Gly Glu Glu Leu Leu</td>
<td></td>
</tr>
<tr>
<td>635</td>
<td>640</td>
</tr>
<tr>
<td>Pro Arg Gly Leu Asp Ile Lys Gln Glu Glu Leu Gly Asp Leu Val</td>
<td></td>
</tr>
<tr>
<td>650</td>
<td>655</td>
</tr>
<tr>
<td>Asp Lys Glu Met Ala Ala Thr Ser Ala Ala Ile Glu Thr Cys Thr</td>
<td></td>
</tr>
<tr>
<td>665</td>
<td>670</td>
</tr>
<tr>
<td>Ala Arg Ile Glu Glu Met Leu Ser Lys Ser Arg Ala Gly Asp Thr</td>
<td></td>
</tr>
<tr>
<td>680</td>
<td>685</td>
</tr>
<tr>
<td>Gly Val Lys Leu Glu Val Asn Glu Arg Ile Leu Arg Cys Cys Thr</td>
<td></td>
</tr>
<tr>
<td>695</td>
<td>700</td>
</tr>
<tr>
<td>Ser Leu Met Gln Ala Ile Gln Val Leu Ile Val Ala Ser Lys Asp</td>
<td></td>
</tr>
<tr>
<td>710</td>
<td>715</td>
</tr>
<tr>
<td>Leu Gln Arg Glu Ile Val Glu Ser Gly Arg Gly Thr Ala Ser Pro</td>
<td></td>
</tr>
<tr>
<td>725</td>
<td>730</td>
</tr>
<tr>
<td>Lys Glu Phe Tyr Ala Lys Asn Ser Arg Trp Thr Glu Gly Leu Ile</td>
<td></td>
</tr>
<tr>
<td>740</td>
<td>745</td>
</tr>
<tr>
<td>Ser Ala Ser Lys Ala Val Gly Trp Gly Ala Thr Val Met Val Asp</td>
<td></td>
</tr>
<tr>
<td>765</td>
<td>770</td>
</tr>
<tr>
<td>Ala Ala Asp Leu Val Val Gln Gly Arg Gly Lys Phe Glu Glu Leu</td>
<td></td>
</tr>
<tr>
<td>780</td>
<td>785</td>
</tr>
<tr>
<td>Met Val Cys Ser His Glu Ile Ala Ala Ser Thr Ala Gln Leu Val</td>
<td></td>
</tr>
<tr>
<td>795</td>
<td>800</td>
</tr>
</tbody>
</table>
(2) INFORMATION FOR SEQ ID NO: 5
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 1090
   (B) TYPE: protein
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
(x) FEATURE: Huntington-interacting protein
(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```
Met Leu Leu Cys Gln Gly Ser Glu Trp Arg Arg Asp Gln Gln Leu
  5
Gly Thr Ala Asn Ala Arg Gln Trp Cys Pro Leu Pro Gln Asp Ala
 20
Gln Pro Ala Gly Ser Trp Glu Arg Cys Pro Pro Leu Pro Pro Ala
 35
Gly Arg Leu Gln Gly Thr Asp His Pro Trp Gly Trp Gly Arg Leu
 50
```

```
Ala Gly Gly Gly Glu Arg Gly Gly Gly Leu Trp Glu Gly Leu Ser His
65           70           75
Ser Gln Arg Leu Ile His Leu Ile Leu Leu Ser Leu Pro Leu Leu
80           85           90
Val Phe Gln Thr Val Ser Ile Asn Lys Ala Ile Asn Thr Gln Glu
95           100          105
Val Ala Val Lys Glu Lys His Ala Arg Thr Cys Ile Leu Gly Thr
110          115          120
His His Glu Lys Gly Ala Gln Thr Phe Trp Ser Val Val Asn Arg
125          130          135
Leu Pro Leu Ser Ser Asn Ala Val Leu Cys Trp Lys Phe Cys His
140          145          150
Val Phe His Lys Leu Leu Arg Asp Gly His Pro Asn Val Leu Lys
155          160          165
Asp Ser Leu Arg Tyr Arg Asn Glu Leu Ser Asp Met Ser Arg Met
170          175          180
Trp Gly His Leu Ser Glu Gly Tyr Gly Gln Leu Cys Ser Ile Tyr
185          190          195
Leu Lys Leu Leu Arg Thr Lys Met Glu Tyr His Thr Lys Asn Pro
200          205          210
Arg Phe Pro Gly Asn Leu Gln Met Ser Asp Arg Gln Leu Asp Glu
215          220          225
Ala Gly Glu Ser Asp Val Asn Asn Phe Phe Gln Leu Thr Val Glu
230          235          240
Met Phe Asp Tyr Leu Glu Cys Glu Leu Asn Leu Phe Gln Thr Val
245          250          255
Phe Asn Ser Leu Asp Met Ser Arg Ser Val Ser Val Thr Ala Ala
260          265          270
Gly Gln Cys Arg Leu Ala Pro Leu Ile Gln Val Ile Leu Asp Cys
275          280          285
Ser His Leu Tyr Asp Tyr Thr Val Lys Leu Leu Phe Lys Leu His
290          295          300
Ser Cys Leu Pro Ala Asp Thr Leu Gln Gly His Arg Asp Arg Phe
305          310          315
<table>
<thead>
<tr>
<th>Residues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met Glu Gln Phe Thr Lys Leu Lys Asp Leu Phe Tyr Arg Ser Ser 320</td>
</tr>
<tr>
<td>Asn Leu Gln Tyr Phe Lys Arg Leu Ile Gln Ile Pro Gln Leu Pro 335</td>
</tr>
<tr>
<td>Glu Asn Pro Pro Asn Phe Leu Arg Ala Ser Ala Leu Ser Glu His 350</td>
</tr>
<tr>
<td>Ile Ser Pro Val Val Val Ile Pro Ala Glu Ala Ser Ser Pro Asp 365</td>
</tr>
<tr>
<td>Ser Glu Pro Val Leu Glu Lys Asp Asp Leu Met Asp Met Asp Ala 380</td>
</tr>
<tr>
<td>Ser Gln Gln Asn Leu Phe Asp Asn Lys Phe Asp Asp Ile Phe Gly 395</td>
</tr>
<tr>
<td>Ser Ser Phe Ser Ser Asp Pro Phe Asn Phe Asn Ser Gln Asn Gly 410</td>
</tr>
<tr>
<td>Val Asn Lys Asp Glu Lys Asp His Leu Ile Glu Arg Leu Tyr Arg 425</td>
</tr>
<tr>
<td>Glu Ile Ser Gly Leu Lys Ala Gln Leu Glu Asn Met Lys Thr Glu 440</td>
</tr>
<tr>
<td>Ser Gln Arg Val Val Leu Gln Leu Lys Gly His Val Ser Glu Leu 455</td>
</tr>
<tr>
<td>Glu Ala Asp Leu Ala Glu Gln Gln His Leu Arg Gln Gln Ala Ala 470</td>
</tr>
<tr>
<td>Asp Asp Cys Glu Phe Leu Arg Ala Glu Leu Asp Glu Leu Arg Arg 485</td>
</tr>
<tr>
<td>Gln Arg Glu Asp Thr Glu Lys Ala Gin Arg Ser Leu Ser Glu Ile 500</td>
</tr>
<tr>
<td>Glu Arg Lys Ala Gln Ala Asn Glu Gln Arg Tyr Ser Lys Leu Lys 515</td>
</tr>
<tr>
<td>Glu Lys Tyr Ser Glu Leu Val Gln Asn His Ala Asp Leu Leu Arg 530</td>
</tr>
<tr>
<td>Lys Asn Ala Glu Val Thr Lys Gln Val Ser Met Ala Arg Gln Ala 545</td>
</tr>
<tr>
<td>Gln Val Asp Leu Glu Arg Glu Lys Lys Glu Leu Glu Asp Ser Leu 560</td>
</tr>
<tr>
<td>Sequence</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Glu Arg Ile Ser Asp Gln Gly Gln Arg Lys Thr Gln Glu Gln Leu</td>
</tr>
<tr>
<td>Glu Val Leu Glu Ser Leu Lys Gln Glu Leu Ala Thr Ser Gln Arg</td>
</tr>
<tr>
<td>Glu Leu Gln Val Leu Gln Gly Ser Leu Glu Thr Ser Ala Gln Ser</td>
</tr>
<tr>
<td>Glu Ala Asn Trp Ala Ala Glu Phe Ala Glu Leu Glu Lys Glu Arg</td>
</tr>
<tr>
<td>Asp Ser Leu Val Ser Gly Ala Ala His Arg Glu Glu Glu Leu Ser</td>
</tr>
<tr>
<td>Ala Leu Arg Lys Glu Leu Gln Asp Thr Gln Leu Lys Leu Ala Ser</td>
</tr>
<tr>
<td>Thr Glu Glu Ser Met Cys Gln Leu Ala Lys Asp Gln Arg Lys Met</td>
</tr>
<tr>
<td>Leu Leu Val Gly Ser Arg Lys Ala Ala Glu Gln Val Ile Gln Asp</td>
</tr>
<tr>
<td>Ala Leu Asn Gln Leu Glu Glu Pro Pro Leu Ile Ser Cys Ala Gly</td>
</tr>
<tr>
<td>Ser Ala Asp His Leu Leu Ser Thr Val Thr Ser Ile Ser Ser Cys</td>
</tr>
<tr>
<td>Ile Glu Gln Leu Glu Lys Ser Trp Ser Gln Tyr Leu Ala Cys Pro</td>
</tr>
<tr>
<td>Glu Asp Ile Ser Gly Leu Leu His Ser Ile Thr Leu Leu Ala His</td>
</tr>
<tr>
<td>Leu Thr Ser Asp Ala Ile Ala His Gly Ala Thr Thr Cys Leu Arg</td>
</tr>
<tr>
<td>Ala Pro Pro Glu Pro Ala Asp Ser Leu Thr Glu Ala Cys Lys Gln</td>
</tr>
<tr>
<td>Tyr Gly Arg Glu Thr Leu Ala Tyr Leu Ala Ser Leu Glu Glu Glu</td>
</tr>
<tr>
<td>Gly Ser Leu Glu Asn Ala Asp Ser Thr Ala Met Arg Asn Cys Leu</td>
</tr>
<tr>
<td>Ser Lys Ile Lys Ala Ile Gly Glu Glu Leu Leu Pro Arg Gly Leu</td>
</tr>
<tr>
<td>WO 99/60986</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Asp Ile Lys Gln Glu Glu Leu Gly Asp Leu Val Asp Lys Glu Met 830 835 840</td>
</tr>
<tr>
<td>Ala Ala Thr Ser Ala Ala Ile Glu Thr Ala Thr Ala Arg Ile Glu 845 850 855</td>
</tr>
<tr>
<td>Glu Met Leu Ser Lys Ser Arg Ala Gly Asp Thr Gly Val Lys Leu 860 865 870</td>
</tr>
<tr>
<td>Glu Val Asn Glu Arg Ile Leu Gly Cys Cys Thr Ser Leu Met Gln 875 880 885</td>
</tr>
<tr>
<td>Ala Ile Gln Val Leu Ile Val Ala Ser Lys Asp Leu Gln Arg Glu 890 895 900</td>
</tr>
<tr>
<td>Ile Val Glu Ser Gly Arg Gly Thr Ala Ser Pro Lys Glu Phe Tyr 905 910 915</td>
</tr>
<tr>
<td>Ala Lys Asn Ser Arg Trp Thr Glu Gly Leu Ile Ser Ala Ser Lys 920 925 930</td>
</tr>
<tr>
<td>Ala Val Gly Trp Gly Ala Thr Val Met Val Asp Ala Ala Ala Asp Leu 930 940 945</td>
</tr>
<tr>
<td>Val Val Gln Gly Arg Gly Lys Phe Glu Glu Leu Met Val Cys Ser 950 955 960</td>
</tr>
<tr>
<td>His Glu Ile Ala Ala Ser Thr Ala Gln Leu Val Ala Ala Ser Lys 965 970 975</td>
</tr>
<tr>
<td>Val Lys Ala Asp Lys Asp Ser Pro Asn Leu Ala Gln Leu Gln Gln Gln 980 985 990</td>
</tr>
<tr>
<td>Ala Ser Arg Gly Val Asn Gln Ala Thr Ala Gly Val Val Ala Ser 995 1000 1005</td>
</tr>
<tr>
<td>Thr Ile Ser Gly Lys Ser Gln Ile Glu Glu Thr Asp Asn Met Asp 1010 1015 1020</td>
</tr>
<tr>
<td>Phe Ser Ser Met Thr Leu Thr Gln Ile Lys Arg Gln Glu Met Asp 1025 1030 1035</td>
</tr>
<tr>
<td>Ser Gln Val Arg Val Leu Glu Leu Glu Asn Glu Leu Gln Lys Glu 1040 1045 1050</td>
</tr>
<tr>
<td>Arg Gln Lys Leu Gly Leu Leu Arg Lys Lys His Tyr Glu Leu Ala 1055 1060 1065</td>
</tr>
<tr>
<td>Gly Val Ala Glu Gly Trp Glu Glu Gly Thr Glu Ala Ser Pro Pro 1070 1075 1080</td>
</tr>
</tbody>
</table>
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3301
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(ix) FEATURE: cDNA for Huntingtin-interacting protein
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CGGTGAGCTG GAGGAGCAGC GGAAGCAGAA GCAGAAGGCC CTGGTGGATA 50
ATGAGCAGCT CGCCACAGAG CTGGCCACC TGAGGCTCGC CACAGTCGAG 100
CGCGAGGCGA GCCGAGGCTGC GCTGAGGAGG GCTCAGGAGA AGCCAGTGC 150
CAGCCAGCGC GCCTACAACA AGCTGAAGGA AAAGCACATG GATGTGCTCC 200
ATGTGCACGC GAGGCTCGTC AGAAAGAAGC CGGAACACAG CAAGCAGCTG 250
ACGGTGCAGGC AGCAAGGCCA GAGGAGGATG GCCGGGAGTA AGAACAGCT 300
GGCTTCCGCT GTGGACGCGA TGAAGGGGCA GCTGGATGTC AAGCTAGAGG 350
AGAAGCAGCG CCAGCAGGAG AAAGCTCAGA GGAGCTGGA GCACACAGCC 400
GGAGAGCTCG CCCGCCGCCA GAGGAGCTCG AGCCACAGAC AGCAAGCAGA 450
GTCGGAGGCTG AGCTACACCT GAGTACACTG AGAGCTGCTG CAGACAGC 500
TGATGAGAGC TGTGCGGCAG CGGAGGACAG ACCTGCTGCG GCCGGGACAG 550
CTGGTGGCGG AGCAAGAACG GCCGAGGCTGC GGGAGACAGC AGCGAGCTG 600
CCAGGAGCGA AGCCGGCGCT AGCGGCGGCT GCAGAGACAG GATCTACGG 650
AGCAGGGCTG CGGCAGGAGG CTGCTGACAG AGCAAGTTCG AGTGCTGCG 700
GGCCGCTCGT CGAGGCGCCG GCCGATCCTG CAGATGCCG TGAGACCTG 750
GGACGACCAC CTGCACCTGC GCTGTACACG CTCCCCAGAC TACCTGCTGA 800
GAGGAGGCCA AGGAGCCTTG GATGCGCTGA GCACCTGCGG AGGGGCGAC 850
GCCAGATACC TGACCTCTTT GCAGAGCCGC TCGCCCTCGG TGACGACCTT 900
GACCAGCTTC TGCCGCTACG CTGGGAACAT GCATCACTCA GGGCGGCGCA 950
CTGCTGACTG GTGTCCACCC AGCGCGTGCT AGCGCGCTAG ACACGGTTCG 1000
AGGAGGATGCG GCCGCCGGGG TCTGAGACCT ATGGGAGCAC TGCAAGACCA 1050
GAGGAGCTCG CGCCACATGC AGGCCGAGCT GTGGAGCGCA CCCTCGCGAG 1100
GCACTCTCTCA GTGGCGCCCA GAACTGAAAC CCAAGACGCT AGATGGCGG 1150
CAGGAGGCAG TGGGGCGCTG GTGCGCAGAAG GAGATGGCGG CCACAGCCTG 1200
AGCCATTGAA GATGCTGCGC GGAGATTTGA GCACTGATG ACCAGGCAC 1250
GCCAGCGCCG CTCGGGGGGG AAGCTGAGAG TGAACGAGAG GACTCCTAAG 1300
TCCTGCAAG ACGTGATGAA GCTGTACCGG CTGCTGCTGGA GCACTCACCC 1350
TAGCTCAGC AGAGAGATCG TGGAGAGCGC GAGGGGGCA GCCAGAGCCG 1400
AGGAAATTTA CGCCGCTGGG GCCTGAAGCG CATGCTGCGA CCATGCGGAA 1450
TCCAAGCGGT TGGGCTGGGG AGACACAGAG CTGCTGAGAG CAGCTGAAAG 1500
GCTGGCTCTT CACGGGCGA AGTATGGAGA GCTCTGCTGC TGCTCCACGC 1550
AGATCAGCGCG CAGCAGCCCG CAGCTGCTGG CGGCCCTCAA GGTGAAGGCC 1600
WO 99/60986

(2) INFORMATION FOR SEQ ID NO: 7
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 676
(B) TYPE: protein
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(ix) FEATURE: Huntingtin-interacting protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Gly Glu Leu Glu Glu Gln Arg Lys Gln Lys Gln Lys Ala Leu Val

16
<table>
<thead>
<tr>
<th>20</th>
<th>Glu</th>
<th>Gln</th>
<th>Leu</th>
<th>Arg</th>
<th>His</th>
<th>Glu</th>
<th>Leu</th>
<th>Ala</th>
<th>Gln</th>
<th>Leu</th>
<th>Arg</th>
<th>Ala</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>Gln</td>
<td>Leu</td>
<td>Glu</td>
<td>Arg</td>
<td>Ser</td>
<td>Gln</td>
<td>Gly</td>
<td>Leu</td>
<td>Arg</td>
<td>Glu</td>
<td>Glu</td>
<td>Ala</td>
<td>Glu</td>
</tr>
<tr>
<td>50</td>
<td>Arg</td>
<td>Lys</td>
<td>Ala</td>
<td>Ser</td>
<td>Ala</td>
<td>Thr</td>
<td>Glu</td>
<td>Ala</td>
<td>Arg</td>
<td>Tyr</td>
<td>Asn</td>
<td>Lys</td>
<td>Leu</td>
</tr>
<tr>
<td>65</td>
<td>Lys</td>
<td>His</td>
<td>Ser</td>
<td>Glu</td>
<td>Leu</td>
<td>Val</td>
<td>His</td>
<td>Val</td>
<td>His</td>
<td>Ala</td>
<td>Glu</td>
<td>Leu</td>
<td>Leu</td>
</tr>
<tr>
<td>80</td>
<td>Asn</td>
<td>Ala</td>
<td>Asp</td>
<td>Thr</td>
<td>Ala</td>
<td>Lys</td>
<td>Gln</td>
<td>Leu</td>
<td>Thr</td>
<td>Val</td>
<td>Thr</td>
<td>Gln</td>
<td>Gln</td>
</tr>
<tr>
<td>95</td>
<td>Glu</td>
<td>Glu</td>
<td>Val</td>
<td>Ala</td>
<td>Arg</td>
<td>Val</td>
<td>Lys</td>
<td>Glu</td>
<td>Gln</td>
<td>Leu</td>
<td>Ala</td>
<td>Phe</td>
<td>Gln</td>
</tr>
<tr>
<td>110</td>
<td>Gln</td>
<td>Val</td>
<td>Lys</td>
<td>Arg</td>
<td>Gln</td>
<td>Ser</td>
<td>Glu</td>
<td>Leu</td>
<td>Lys</td>
<td>Leu</td>
<td>Glu</td>
<td>Glu</td>
<td>Lys</td>
</tr>
<tr>
<td>125</td>
<td>Gln</td>
<td>Gln</td>
<td>Glu</td>
<td>Lys</td>
<td>Leu</td>
<td>Lys</td>
<td>Arg</td>
<td>Glu</td>
<td>Leu</td>
<td>Gln</td>
<td>Ala</td>
<td>Lys</td>
<td>Ala</td>
</tr>
<tr>
<td>140</td>
<td>Leu</td>
<td>Ala</td>
<td>Arg</td>
<td>Ala</td>
<td>Gln</td>
<td>Glu</td>
<td>Ala</td>
<td>Leu</td>
<td>Ser</td>
<td>His</td>
<td>Thr</td>
<td>Glu</td>
<td>Gln</td>
</tr>
<tr>
<td>155</td>
<td>Ser</td>
<td>Glu</td>
<td>Leu</td>
<td>Ser</td>
<td>Arg</td>
<td>Leu</td>
<td>Asp</td>
<td>Thr</td>
<td>Leu</td>
<td>Ser</td>
<td>Ala</td>
<td>Glu</td>
<td>Lys</td>
</tr>
<tr>
<td>170</td>
<td>Ala</td>
<td>Leu</td>
<td>Ser</td>
<td>Gly</td>
<td>Ala</td>
<td>Val</td>
<td>Arg</td>
<td>Gln</td>
<td>Arg</td>
<td>Gln</td>
<td>Ala</td>
<td>Asp</td>
<td>Leu</td>
</tr>
<tr>
<td>185</td>
<td>Ala</td>
<td>Gln</td>
<td>Ser</td>
<td>Leu</td>
<td>Val</td>
<td>Arg</td>
<td>Glu</td>
<td>Thr</td>
<td>Glu</td>
<td>Ala</td>
<td>Ala</td>
<td>Leu</td>
<td>Ser</td>
</tr>
<tr>
<td>200</td>
<td>Gln</td>
<td>Gln</td>
<td>Arg</td>
<td>Ser</td>
<td>Gln</td>
<td>Glu</td>
<td>Gln</td>
<td>Gly</td>
<td>Glu</td>
<td>Leu</td>
<td>Gln</td>
<td>Gly</td>
<td>Arg</td>
</tr>
<tr>
<td>215</td>
<td>Ala</td>
<td>Glu</td>
<td>Arg</td>
<td>Glu</td>
<td>Ser</td>
<td>Gln</td>
<td>Glu</td>
<td>Gln</td>
<td>Gly</td>
<td>Leu</td>
<td>Arg</td>
<td>Gln</td>
<td>Arg</td>
</tr>
<tr>
<td>230</td>
<td>Asp</td>
<td>Glu</td>
<td>Gln</td>
<td>Phe</td>
<td>Ala</td>
<td>Val</td>
<td>Leu</td>
<td>Arg</td>
<td>Gly</td>
<td>Ala</td>
<td>Ala</td>
<td>Ala</td>
<td>Glu</td>
</tr>
<tr>
<td>245</td>
<td>Gly</td>
<td>Ile</td>
<td>Leu</td>
<td>Gln</td>
<td>Asp</td>
<td>Ala</td>
<td>Val</td>
<td>Ser</td>
<td>Lys</td>
<td>Leu</td>
<td>Asp</td>
<td>Asp</td>
<td>Pro</td>
</tr>
<tr>
<td>260</td>
<td>Leu</td>
<td>Arg</td>
<td>Cys</td>
<td>Thr</td>
<td>Ser</td>
<td>Ser</td>
<td>Pro</td>
<td>Asp</td>
<td>Tyr</td>
<td>Leu</td>
<td>Val</td>
<td>Ser</td>
<td>Arg</td>
</tr>
</tbody>
</table>
Glu Ala Leu Asp Ala Val Ser Thr Leu Glu Glu Gly His Ala Gln
    275                  288                  285
Tyr Leu Thr Ser Leu Ala Asp Ala Ser Ala Leu Val Ala Ala Leu
    290                  295                  300
Thr Arg Phe Ser His Leu Ala Ala Asp Thr Ile Ile Asn Gly Gly
    305                  310                  315
Ala Thr Ser His Leu Ala Pro Thr Asp Pro Ala Asp Arg Leu Ile
    320                  325                  330
Asp Thr Cys Arg Glu Cys Gly Ala Arg Ala Leu Glu Leu Met Gly
    335                  340                  345
Gln Leu Gln Asp Gln Gln Ala Leu Arg His Met Gln Ala Ser Leu
    350                  355                  360
Val Arg Thr Pro Leu Gln Gly Ile Leu Gln Leu Gly Gln Glu Leu
    365                  370                  375
Lys Pro Lys Ser Leu Asp Val Arg Gln Glu Glu Leu Gly Ala Val
    380                  385                  390
Val Asp Lys Glu Met Ala Ala Thr Ser Ala Ala Ile Glu Asp Ala
    395                  400                  405
Val Arg Arg Ile Glu Asp Met Met Asn Gln Ala Arg His Ala Ser
    410                  415                  420
Ser Gly Val Lys Leu Glu Val Asn Glu Arg Ile Leu Asn Ser Cys
    425                  430                  435
Thr Asp Leu Met Lys Ala Ile Arg Leu Leu Val Thr Thr Ser Thr
    440                  445                  450
Ser Leu Gln Lys Glu Ile Val Glu Ser Gly Arg Gly Ala Ala Thr
    455                  460                  465
Gln Gln Glu Phe Tyr Ala Lys Asn Ser Arg Trp Thr Glu Gly Leu
    470                  475                  480
Ile Ser Ala Ser Lys Ala Val Gly Trp Gly Ala Thr Gln Leu Val
    485                  490                  495
Glu Ala Ala Asp Lys Val Val Leu His Thr Gly Lys Tyr Glu Glu
    500                  505                  510
Leu Ile Val Cys Ser His Glu Ile Ala Ala Ser Thr Ala Gln Leu
    515                  520                  525
Val Ala Ala Ser Lys Val Lys Ala Asn Lys His Ser Pro His Leu 530 535 540
Ser Arg Leu Gln Glu Cys Ser Arg Thr Val Asn Glu Arg Ala Ala 545 550 555
Asn Val Val Ala Ser Thr Lys Ser Gly Gln Glu Gln Ile Glu Asp 560 565 570
Arg Asp Thr Met Asp Phe Ser Gly Leu Ser Leu Ile Lys Leu Lys 575 580 585
Lys Gln Glu Met Glu Thr Gln Val Arg Val Leu Glu Leu Glu Lys 590 595 600
Thr Leu Glu Ala Glu Arg Met Arg Leu Gly Glu Leu Arg Lys Gln 605 610 615
His Tyr Val Leu Ala Gly Ala Ser Gly Ser Pro Gly Glu Glu Val 620 625 630
Ala Ile Arg Pro Ser Thr Ala Pro Arg Ser Val Thr Thr Lys Lys 635 640 645
Pro Pro Leu Ala Gln Lys Pro Ser Val Ala Pro Arg Gln Asp His 650 655 660
Gln Leu Asp Lys Lys Asp Gly Ile Tyr Pro Ala Gln Leu Val Asn 665 670 675

Tyr

(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2338
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: mouse
(xi) FEATURE: cDNA for Huntingtin-interacting protein - mHIP1
(x) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
GGCACGAGGG CTATTCAGA TCCCCAGCT GCCGAGAAT CCACCACTTT 50
CCTACGAGCC TCGCCGCTGT CAGAGACAT CAGTCCTGTC GTGGTGTCC 100
GCCAGAGGTC TCATCCCGAGCAGATGCAGGGGTTCGTGAAGGATGACCT 150
CATGGCATG GACGCCTCCC AGCAGACCTTTGATGACACAC 200
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 676
   (B) TYPE: protein
   (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: mouse
(ix) FEATURE: Huntingtin-interacting protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

<table>
<thead>
<tr>
<th>Ala</th>
<th>Arg</th>
<th>Gly</th>
<th>Leu</th>
<th>Ile</th>
<th>Gln</th>
<th>Ile</th>
<th>Pro</th>
<th>Gln</th>
<th>Leu</th>
<th>Pro</th>
<th>Glu</th>
<th>Asn</th>
<th>Pro</th>
<th>Pro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asn</th>
<th>Phe</th>
<th>Leu</th>
<th>Arg</th>
<th>Ala</th>
<th>Ser</th>
<th>Ala</th>
<th>Leu</th>
<th>Ser</th>
<th>Glu</th>
<th>His</th>
<th>Ile</th>
<th>Ser</th>
<th>Pro</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Val</th>
<th>Val</th>
<th>Ile</th>
<th>Pro</th>
<th>Ala</th>
<th>Glu</th>
<th>Val</th>
<th>Ser</th>
<th>Ser</th>
<th>Pro</th>
<th>Asp</th>
<th>Ser</th>
<th>Glu</th>
<th>Pro</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>45</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Glu</th>
<th>Lys</th>
<th>Asp</th>
<th>Asp</th>
<th>Leu</th>
<th>Met</th>
<th>Asp</th>
<th>Met</th>
<th>Asp</th>
<th>Ala</th>
<th>Ser</th>
<th>Gln</th>
<th>Gln</th>
<th>Thr</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td></td>
<td></td>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Phe</th>
<th>Asp</th>
<th>Asn</th>
<th>Lys</th>
<th>Phe</th>
<th>Asp</th>
<th>Asp</th>
<th>Val</th>
<th>Phe</th>
<th>Gly</th>
<th>Ser</th>
<th>Ser</th>
<th>Leu</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>65</td>
<td></td>
<td></td>
<td>70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ser</th>
<th>Asp</th>
<th>Pro</th>
<th>Phe</th>
<th>Asn</th>
<th>Phe</th>
<th>Asn</th>
<th>Asn</th>
<th>Gln</th>
<th>Asn</th>
<th>Gly</th>
<th>Val</th>
<th>Asn</th>
<th>Lys</th>
<th>Asp</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>80</td>
<td></td>
<td></td>
<td>85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glu</th>
<th>Lys</th>
<th>Asp</th>
<th>His</th>
<th>Leu</th>
<th>Ile</th>
<th>Glu</th>
<th>Arg</th>
<th>Leu</th>
<th>Tyr</th>
<th>Arg</th>
<th>Glu</th>
<th>Ile</th>
<th>Ser</th>
<th>Gly</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>95</td>
<td></td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>105</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Thr</th>
<th>Gly</th>
<th>Gln</th>
<th>Leu</th>
<th>Asp</th>
<th>Met</th>
<th>Lys</th>
<th>Ile</th>
<th>Glu</th>
<th>Ser</th>
<th>Gln</th>
<th>Arg</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>110</td>
<td></td>
<td></td>
<td>115</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>120</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Met</th>
<th>Leu</th>
<th>Gln</th>
<th>Leu</th>
<th>Lys</th>
<th>Gly</th>
<th>Arg</th>
<th>Val</th>
<th>Ser</th>
<th>Glu</th>
<th>Leu</th>
<th>Glu</th>
<th>Ala</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>125</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>130</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ala</th>
<th>Glu</th>
<th>Gln</th>
<th>His</th>
<th>Leu</th>
<th>Gly</th>
<th>Arg</th>
<th>Gln</th>
<th>Ala</th>
<th>Met</th>
<th>Asp</th>
<th>Asp</th>
<th>Cys</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>140</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>145</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phe</th>
<th>Leu</th>
<th>Arg</th>
<th>Thr</th>
<th>Glu</th>
<th>Leu</th>
<th>Asp</th>
<th>Glu</th>
<th>Leu</th>
<th>Lys</th>
<th>Arg</th>
<th>Gln</th>
<th>Arg</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>155</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>160</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Thr</th>
<th>Glu</th>
<th>Lys</th>
<th>Ala</th>
<th>Gln</th>
<th>Arg</th>
<th>Ser</th>
<th>Leu</th>
<th>Thr</th>
<th>Glu</th>
<th>Ile</th>
<th>Glu</th>
<th>Arg</th>
<th>Lys</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>175</td>
<td>180</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gln</th>
<th>Ala</th>
<th>Asn</th>
<th>Glu</th>
<th>Gln</th>
<th>Arg</th>
<th>Tyr</th>
<th>Ser</th>
<th>Lys</th>
<th>Leu</th>
<th>Lys</th>
<th>Glu</th>
<th>Lys</th>
<th>Tyr</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>185</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glu</th>
<th>Leu</th>
<th>Val</th>
<th>Gln</th>
<th>Asn</th>
<th>His</th>
<th>Ala</th>
<th>Asp</th>
<th>Leu</th>
<th>Arg</th>
<th>Lys</th>
<th>Asn</th>
<th>Ala</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>200</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Val</th>
<th>Thr</th>
<th>Lys</th>
<th>Gln</th>
<th>Val</th>
<th>Ser</th>
<th>Val</th>
<th>Ala</th>
<th>Arg</th>
<th>Gln</th>
<th>Ala</th>
<th>Gln</th>
<th>Val</th>
<th>Asp</th>
<th>Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>215</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glu</th>
<th>Arg</th>
<th>Glu</th>
<th>Lys</th>
<th>Lys</th>
<th>Glu</th>
<th>Leu</th>
<th>Ala</th>
<th>Asp</th>
<th>Ser</th>
<th>Phe</th>
<th>Ala</th>
<th>Arg</th>
<th>Val</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>220</td>
</tr>
</tbody>
</table>

|     |     |     |     |     |     |     |     |     |     |     |     |     |     | 225 |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     | 230 |

21
<table>
<thead>
<tr>
<th>230</th>
<th>235</th>
<th>240</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asp</td>
<td>Gln</td>
<td>Ala</td>
</tr>
<tr>
<td>245</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asn</td>
<td>Leu</td>
<td>Lys</td>
</tr>
<tr>
<td>260</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>His</td>
<td>Ser</td>
</tr>
<tr>
<td>275</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Thr</td>
<td>Gln</td>
</tr>
<tr>
<td>290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
<td>Ala</td>
</tr>
<tr>
<td>305</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Leu</td>
<td>Glu</td>
</tr>
<tr>
<td>320</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Met</td>
<td>Cys</td>
<td>Gln</td>
</tr>
<tr>
<td>335</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Arg</td>
<td>Lys</td>
</tr>
<tr>
<td>350</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Glu</td>
<td>Glu</td>
</tr>
<tr>
<td>365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Leu</td>
<td>Ser</td>
</tr>
<tr>
<td>380</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu</td>
<td>Lys</td>
<td>Asn</td>
</tr>
<tr>
<td>395</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu</td>
<td>Leu</td>
<td>Leu</td>
</tr>
<tr>
<td>410</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>425</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro</td>
<td>Ala</td>
<td>Asp</td>
</tr>
<tr>
<td>440</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Leu</td>
<td>Ala</td>
</tr>
<tr>
<td>455</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asn</td>
<td>Ala</td>
<td>Asp</td>
</tr>
<tr>
<td>470</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thr Leu Gly Glu Glu Leu Leu Pro Arg Gly Leu Asp Ile Lys Gln
485
Glu Glu Leu Gly Asp Leu Val Asp Lys Glu Met Ala Ala Thr Ser
500
505
510
Ala Ala Ile Glu Ala Ala Thr Thr Arg Ile Glu Glu Ile Leu Ser
515
520
525
Lys Ser Arg Ala Gly Asp Thr Gly Val Lys Leu Glu Val Asn Glu
530
535
540
Arg Ile Leu Gly Ser Cys Thr Ser Leu Met Gln Ala Ile Lys Val
545
550
555
Leu Val Val Ala Ser Lys Asp Leu Gln Lys Glu Ile Val Glu Ser
560
565
570
Gly Arg Gly Ser Ala Ser Pro Lys Glu Phe Tyr Ala Lys Asn Ser
575
588
585
Arg Trp Thr Glu Gly Leu Ile Ser Ala Ser Lys Ala Val Gly Trp
590
595
600
Gly Ala Thr Ile Met Val Asp Ala Ala Asp Leu Val Val Gln Gly
605
610
615
Lys Gly Lys Phe Glu Glu Leu Met Val Cys Ser Arg Glu Ile Ala
620
625
630
Ala Ser Thr Ala Gln Leu Val Ala Ala Ser Lys Val Lys Ala Asn
635
640
645
Lys Gly Ser Leu Asn Leu Thr Gln Leu Gln Gln Ala Ser Arg Gly
650
655
660
Val Asn Gln Ala Thr Ala Ala Val Val Ala Ser Thr Ile Ser Gly
665
670
675
Lys Ser Gln Ile Glu Glu Thr Asp Ser Met Asp Phe Ser Ser Met
680
685
690
Thr Leu Thr Gln Ile Lys Arg Gln Glu Met Asp Ser Gln Val Arg
695
700
705
Val Leu Glu Leu Glu Asn Asp Leu Gln Lys Glu Arg Gln Lys Leu
710
715
720
Gly Glu Leu Arg Lys Lys His Tyr Glu Leu Glu Gly Val Ala Glu
725
730
735
WO 99/60986

Gly Trp Glu Glu Gly Thr Glu Ala Ser Pro Ser Thr Val Gln Glu
740
745
750

Ala Ile Pro Asp Lys Glu

755

(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3964
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: mouse
(ix) FEATURE: cDNA for Huntingtin-interacting protein - mHIP1a
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
GGCACGAGGC GGGCGCGCCG CTCCGTGTGC CTaggcttga GGGGCGCGT 50
GACGGCTCAT TCAGCAGGGG CCGGGGCGGG ACAGGCTCGG CCGGAGCATG 100
AAAGCATCA AAGTGTCGTC GGGCGGTGGT CGTAGCCGCA GGGCGGGCA 150
CAAGCTACAG CAGGAGCGCG AGCAATGCGA CAAGACGGCG GCCATCAGT 200
TCAGCAAGGC CATCAACAGC CAGGAGCCCC CAGTAGGAGA GAAGCATGCG 250
CGGCGTATCA TCGTAGGCCA GACATCGAG AAGGAGCTT TCAGCTCTCG 300
GTCTATGGCC ATCAGCGCCTTC CGCTGTCGCC CAGCTCCTCC TCAGCTCGGA 350
AGTCCTGCTA CTCGATTTCC AAGGCTCTCC GGGAGGGACA CCCAAGCTC 400
CTGCTAGACT ATCAGGGTAA CCGGACGCAA ATACCTGGAA TCGGGCTACTT 450
GGTGCGCCAC CTGCGGGACC AGTATGGACA CCGGCTGAAT ATCTATACCA 500
AAGCTTGGCT GACTAAGATC TCCGCTACCA TAAAGCCACC CCAGGCTTCT 550
GGCGGCTGGG AGTACGAGCA TCAGAGCGCA GAGGGGAGCA CCCAGGAGG 600
TTAAGCCTGG AGTGCTTGTC CCGGAGAGGC GGGTGCTGAC GGGGCTGCA 650
AGGTCGTGCA AGGCTGACCC TGGGGGCGCC TGGGCGGGCA TGGGCGGGG 700
GGTTAGCTCC ATCAGGGTCC TGGGCGGGCT GGGGCTCCGA CCCCAGGGG 750
GGTCTACAG GACTGACGCC ACCCTGAGCA CTAGACAGTG AAGCTGATGT 800
TTAAGCTGGG AGTGCTTGTC CCGGAGAGGC GGGTGCTGAC GGGGCTGCA 850
CGGCTGACCC ATCAGGGTCC TGGGCGGGCT GGGGCTCCGA CCCCAGGGG 900
AGGACTGCTG TACTTCAAGA GGGTCAACCC CAGGCGCCGG CTGCTGAGG 950
GACCCCCAAA TTTCTGCGGC GCTTGACGCC TGGGCTGAGC CATCAAGGCC 1000
GGTGTTGGGA TTTCCCGAGGA GGGCCAGAGG AAGAGGGAGG CTGAGCAACTT 1050
AATTTAATATC AGCAAGCGCG CCCCCTGGTG GAGGCCAGTG GTGGTGCGCT 1100
ACCTTTTGGG TTAGAGCCCA ATGCTGACC ATGAGGTAAG 1150
AGGCGACCTCC AATCAGGAGA CTGAGGGAGA GAGGGGCGCC CCCCCTGGTG 1200
TGAGCTGAGG AAGTTTAAAGA TGAGCAGGCA GGGTACACCC TCCAGCTGCA 1250
AGGGCCAGGT GAAATGGGCGA GGGAGGAGAG CTTAGGGAGA CAGGACAGG 1300
AAGCAAGAGG CCCGGGCGCC GAGCGGAGCA CTGCGGCGGA AGCTGGCCCA 1350
GCTAGACGCC CTGCGTGAGG AGGCGGGGCG CAAAAGGAGA CTTAGGGAGA 1400
AAGCAAGAGG GAGGCGCAAC CGCGGAGGG CAGCTCAGAG AAGGCTAAGG 1450
GAGAAACACA GCGAACTCAT TAAAGGGCCG GGGGCTGAGG CTGAGGAAGA 1500
```
CGCAGACAGC GCCAACAGGC TGACAGTGAC ACAGCAGAC CAGGAGGAGG 1550
TGGCAGCGGTA AAGGAAGACG CTTGCGCCTCC AGATGGAGCC AAGCAGGCTT 1600
GATGCCTGAGA TGAGATGCTGA AGAGCAGACC GACCAGTTTG AGAAGCTCAA 1650
GAGGGAGCTG GGCGGGACGG AGGGAGCTG GGCGGGAGCC AGGGAGGCCC 1700
TGAGCCGACG AGAACAGACT GGTCTCAGAC TGAGCTCACG TGCTGACACA 1750
CTGAGAAGCG AGAGGAGAAC CCTGAGTTGA GTGCTTGGCC AGGCTGAGGC 1800
AGAGCAGTCTG GCCGGCTGCA GGCTGCTGCG GGAAGAGAGG GAGGGCTTTA 1850
GCCAGAGCCA GCAGCGGACG TCCCAAGGAA AGGCGGAGCT ACGGGGGAGG 1900
CTGGCAGAAAG AGAGGATCTCA GGGCAGGGG CTTCGCGACGA AGCTGCTGGA 1950
TGAGACAGATG CCGTGTGTCG GAAAGTGACG CCGCAGGAGA CGACCATTC 2000
TACAGGATGCG AGTAGAGCAAG CTGAGCAGCC CCTGACCACT CCGCTGCAAC 2050
AGCTCCCGAG ACTACTTGGTT GAGCGGCGTG CAGCGAGCCC TGAGCAGCGT 2100
QAAGCGCCGC CAGAAAAGTG CCACTGCTCC CCTAGGAAAC TCCGCAAGTC 2150
CTTCTGCTCCT GGTGCGCAGCG TGACAGCGGT TCTTTCCATTT GCTGCGGAGC 2200
ACCATTTGCTA ATGGCGTGCA CACCTCCTAC CTGGCTCCCA CGAACCCCGC 2250
CGAGCAGCCG ATGCAAACGTG CAGCAGAGTT TTGGAGCGTG CCGTGAGACC 2300
TGAGGACGACA GCTGCGACAG ACAGACTGGC TAGGAGGAGC TCAGCGAGGC 2350
CTGATTGGCG CCCCCGCGCA GGGACTGTTC AGCTTGAGGG GAGACCTGA 2400
GCTTTAGAGG CTTGCTAGAC CGAAGAGAGA GTAGGGGCCT GTGAGGACAG 2450
AGAGAATGCC GCCACCTTGG GCCAGGCTTG AGAGCAGCTG GAGGGAGATC 2500
GAGAGCTAAG TGAAGCAGCC GCCGAGCGGC AGCTGCTGAG TGAAAATCGGA 2550
GGTGAAATGAG AGAATGCTCA ACTCTGTCAG ACAGCAGTGAT AGGGTATCC 2600
GCCCTCTCTG CCCTGCTCCG AGAAGAATGG TTTGGAAGCG AGGGAGAGCG 2650
GCCAGGGGGA CAGCGAACCA GCAGATTATA ATGGCAGACA ATTCAGGCTG 2700
GACTGGAAAC CTCACTACAA CGTCAGCGAG ATGGCGGTGG GGAGGACACA 2750
AGTGTGGCTGA GTAGCTGTAC AAGGTTGTGC TTCTACATGG CAAATACAGA 2800
GAACCTCTCG TCTGCTCCAG TGAGATTGCG GCCAGAGGCG CCGAGCTCGT 2850
GCCAGCCCTG AGGTGAAGAC CCAACAGGAAG CAGTCCCTCC TTGGAGGCGT 2900
TGCGAGCTAG TCCGGCAACT TAGCAGGAGA GGGCTGCCAA GCTGCTGCCG 2950
TCCACAATA GCTGGCGAGA GAGATGGTGAG CAGAGAGACA CATGGATTT 3000
CTTCGCGCCTG TCCACTCAGA AGTCTGAAGA GCAGGACAGT GACAGACAG 3050
TGCGACTCTT GGAGCGTTAG AAGACACATG AGGCGAGGCG TGTCGGGCTC 3100
GGGAGCTTCC GGAAACACGA CTAATCTACT GCTGGAGGGA TGGAGGACCC 3150
TAGAGAAAGA GAACCGCAAG CAGCCAGCCC AGCTCCCCGA AGTGAGGCCA 3200
CTAAGGACCC ACCGCTGCGC CAGAAACGAA CAGTACCGGG CAGAGACAG 3250
AACAAGCTCGA CAAAAAGGAT GTGGTGCTACC CAGCTCAGAC TGGCTGACTC 3300
TAGGGCCCTAA GTGTGGTACG AGAGTGGGCTGT GTGGTGGTGC TGTCGGCTTCA 3350
TGTTACCTCTG CAGATGCTGAC AAGAGGCCCC TGAAGGCTCG CAACTCTCTG 3400
CCCAAGGGCCC TAGTCTGCTG GACAGACTCA CTGGATGTAC ATCTACATAT 3450
CTTAAGTACG ACGCTCCGAG GCAGCTGGGA CCCAGCGAGC CGAGCCACA 3500
AATCTCGACGG CAACACAGAG ATAGCTCAGG TGCTGGCAGGA TTCTCCTTTT 3550
TTTGTAAGTTT AGTCACAGCA CTGGGAAAG GTCACTAAG CGAGGACCCCT 3600
CCTGTGCTCTG GACTCAAAAG TCTGAGGSCCT TAAATGGAACA ACAAAAAGA 3650
GGTTCCTGGTGT CAGATGGGCAC ATAAGGGGAT GACCTGCTGC CCGAGCTCAG 3700
GGAGAGCGAGG TAAGCTGGGT GTGTGCTACCA CCTGGGGGCG TGTTGCTAGG 3750
GGCGCAGGCCA GGAGCGAGGC CTTTGTGGTG GAGCGCTGCC TGCAGCAGCC 3800
TGACTCGGCTCC GGCGGACGCC CTGCTCAGGA GTGCTCCTCC CCCGTCAGCC 3850
TGAAGCCACC TCCCAGCTGA CAGTTTCTCG TTCCTCGGGC TACTAGTGTTG 3900
GCTGTTCAATTG CCTACCTGTA TGAGTAGATT TCAGCCCTCC TAAAGCTGGG 3950
GGCTTTGCTCAG TGCC
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 676
(B) TYPE: protein
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: mouse
(ix) FEATURE: Huntingtin-interacting protein -mHIP1a
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

```
Met Asn Ser Ile Lys Asn Val Pro Ala Arg Val Leu Ser Arg Arg
   5
Pro Gly His Ser Leu Glu Ala Glu Arg Glu Gln Phe Asp Lys Thr
  20
Gln Ala Ile Ser Ile Ser Lys Ala Ile Asn Ser Gln Glu Ala Pro
  35
Val Lys Glu Lys His Ala Arg Arg Ile Ile Leu Gly Thr His His
  50
  55
Glu Lys Gly Ala Phe Thr Phe Trp Ser Tyr Ala Ile Gly Leu Pro
  65
  70
Leu Ser Ser Ser Ser Ile Leu Ser Trp Lys Phe Cys His Val Leu
  80
  85
His Lys Val Leu Arg Asp Gly His Pro Asn Val Leu His Asp Tyr
  95
 100
Gln Arg Tyr Arg Ser Asn Ile Arg Glu Ile Gly Asp Leu Trp Gly
 110
 115
His Leu Arg Asp Gln Tyr Gly His Leu Val Asn Ile Tyr Thr Lys
 125
 130
Leu Leu Leu Thr Lys Ile Ser Phe His Leu Lys His Pro Gln Phe
 140
 145
Pro Ala Gly Leu Glu Val Thr Asp Glu Val Leu Glu Lys Ala Ala
 155
 160
Gly Thr Asp Val Asn Ile Phe Gln Leu Thr Val Glu Met Phe
 170
 175
Asp Tyr Met Asp Cys Glu Leu Lys Leu Ser Glu Ser Val Phe Arg
```
Gln Leu Asn Thr Ala Ile Ala Val Ser
Cys Arg Leu Ala Pro Leu Ile Gln Val
Leu Tyr His Tyr Thr Val Lys Leu Met
Leu Pro Ala Asp Thr Leu Gln Gly His
Gln Phe His Ser Leu Lys Asn Phe Phe
Leu Tyr Phe Lys Arg Leu Ile Gln Ile
Pro Pro Asn Phe Leu Arg Ala Ser Ala
Pro Val Val Val Ile Pro Glu Glu Ala
Glu Asn Leu Ile Glu Ile Ser Ser Ala
Val Val Val Ala Asp Leu Phe Asp Gln
Gly Ser Met Lys Asp Arg Asp Leu Gln Ile Glu Asn Leu
Arg Glu Val Glu Thr Leu Arg Ala Glu
Glu Ala Gln Arg Tyr Ile Ser Gln Leu Lys Gly Gln Val Asn Gly
Leu Glu Ala Glu Leu Glu Glu Gln Arg Lys Gln Lys Gln Lys Ala
Leu Val Asp Asn Glu Gln Leu Arg His Glu Leu Ala Gln Leu Lys
 Ala Leu Gln Leu Glu Gly Ala Arg Asn Gln Gly Leu Arg Glu Glu
 Ala Glu Arg Lys Ala Ser Ala Thr Glu Ala Arg Tyr Ser Lys Leu
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>440</td>
<td>445</td>
<td>450</td>
</tr>
<tr>
<td>Lys Glu Lys His Ser Glu Leu Ile Asn Thr His Ala Glu Leu Leu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>455</td>
<td>460</td>
<td>465</td>
</tr>
<tr>
<td>Arg Lys Asn Ala Asp Thr Ala Lys Gln Leu Thr Val Thr Gln Gln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>470</td>
<td>475</td>
<td>480</td>
</tr>
<tr>
<td>Ser Gln Glu Glu Val Ala Arg Val Lys Glu Gln Leu Ala Phe Gln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>485</td>
<td>490</td>
<td>495</td>
</tr>
<tr>
<td>Met Glu Gln Ala Lys Arg Glu Ser Glu Met Lys Met Glu Glu Gln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>505</td>
<td>510</td>
</tr>
<tr>
<td>Ser Asp Gln Leu Glu Lys Leu Lys Arg Glu Leu Ala Ala Arg Ala</td>
<td></td>
<td></td>
</tr>
<tr>
<td>515</td>
<td>520</td>
<td>525</td>
</tr>
<tr>
<td>Gly Glu Leu Ala Arg Ala Gln Glu Ala Leu Ser Arg Thr Glu Gln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>530</td>
<td>535</td>
<td>540</td>
</tr>
<tr>
<td>Ser Gly Ser Glu Leu Ser Ser Arg Leu Asp Thr Leu Asn Ala Glu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>545</td>
<td>550</td>
<td>555</td>
</tr>
<tr>
<td>Lys Glu Ala Leu Ser Gly Val Val Arg Gln Arg Glu Ala Glu Leu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>560</td>
<td>565</td>
<td>570</td>
</tr>
<tr>
<td>Leu Ala Ala Gln Ser Leu Val Arg Glu Lys Glu Glu Ala Leu Ser</td>
<td></td>
<td></td>
</tr>
<tr>
<td>575</td>
<td>580</td>
<td>585</td>
</tr>
<tr>
<td>Gln Glu Gln Gln Arg Ser Ser Gln Glu Lys Gly Glu Leu Arg Gly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>590</td>
<td>595</td>
<td>600</td>
</tr>
<tr>
<td>Gln Leu Ala Glu Lys Glu Ser Gln Glu Gln Gly Leu Arg Gln Lys</td>
<td></td>
<td></td>
</tr>
<tr>
<td>605</td>
<td>610</td>
<td>615</td>
</tr>
<tr>
<td>Leu Leu Asp Glu Gln Leu Ala Val Leu Arg Ser Ala Ala Ala Glu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>620</td>
<td>625</td>
<td>630</td>
</tr>
<tr>
<td>Ala Glu Ala Ile Leu Gln Asp Ala Val Ser Lys Leu Asp Asp Pro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>635</td>
<td>640</td>
<td>645</td>
</tr>
<tr>
<td>Leu His Leu Arg Cys Thr Ser Ser Pro Asp Tyr Leu Val Ser Arg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>650</td>
<td>655</td>
<td>660</td>
</tr>
<tr>
<td>Ala Gln Ala Ala Leu Asp Ser Val Ser Gly Leu Glu Gln Gly His</td>
<td></td>
<td></td>
</tr>
<tr>
<td>665</td>
<td>670</td>
<td>675</td>
</tr>
<tr>
<td>Thr Gln Tyr Leu Ala Ser Ser Glu Asp Ala Ser Ala Leu Val Ala</td>
<td></td>
<td></td>
</tr>
<tr>
<td>680</td>
<td>685</td>
<td>690</td>
</tr>
<tr>
<td>Ala Leu Thr Arg Phe Ser His Leu Ala Ala Asp Thr Ile Val Asn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Gly Ala Ala Thr Ser His Leu Ala Pro Thr Asp Pro Ala Asp Arg
710  715  720
Leu Met Asp Thr Cys Arg Glu Cys Gly Ala Arg Ala Leu Glu Leu
725  730  735
Val Gly Gln Leu Gln Asp Gln Thr Val Leu Arg Arg Ala Gln Pro
740  745  750
Ser Leu Met Arg Ala Pro Leu Gln Gly Ile Leu Gln Leu Gly Gln
755  760  765
Asp Leu Lys Pro Lys Ser Leu Asp Val Arg Gln Glu Glu Leu Gly
770  775  780
Ala Met Val Asp Lys Glu Met Ala Ala Thr Ser Ala Ala Ile Glu
785  790  795
Asp Ala Val Arg Arg Ile Glu Asp Met Met Ser Gln Ala Arg His
800  805  810
Glu Ser Ser Gly Val Lys Leu Glu Val Asn Glu Arg Ile Leu Asn
815  820  825
Ser Cys Thr Asp Leu Met Lys Ala Ile Arg Leu Leu Val Met Thr
830  835  840
Ser Thr Ser Leu Gln Lys Glu Ile Val Glu Ser Gly Arg Gly Ala
845  850  855
Ala Thr Gln Gln Glu Phe Tyr Ala Lys Asn Ser Arg Trp Thr Glu
860  865  870
Gly Leu Ile Ser Ala Ser Lys Ala Val Gly Trp Gly Ala Thr Gln
875  880  885
Leu Val Glu Ser Ala Asp Lys Val Val Leu His Met Gly Lys Tyr
890  895  900
Glu Glu Leu Ile Val Cys Ser His Glu Ile Ala Ala Ser Thr Ala
905  910  915
Gln Leu Val Ala Ala Ser Lys Val Lys Ala Asn Lys Asn Ser Pro
920  925  930
His Leu Ser Arg Leu Gln Glu Cys Ser Arg Thr Val Asn Glu Arg
935  940  945
Ala Ala Asn Val Val Ala Ser Thr Lys Ser Gly Gln Glu Gln Ile
Glu Asp Arg Asp Thr Met Asp Phe Ser Gly Leu Ser Leu Ile Lys
950 955 960
Leu Lys Lys Gln Glu Met Glu Thr Gln Val Arg Val Leu Glu Leu
965 970 975
Glu Lys Thr Leu Glu Ala Glu Arg Val Arg Leu Gly Glu Leu Arg
980 985 990
Lys Gln His Tyr Val Leu Ala Gly Gly Met Gly Thr Pro Ser Glu
995 1100 1105
Glu Glu Pro Ser Arg Pro Ser Pro Ala Pro Arg Ser Gly Ala Thr
1110 1115 1120
Lys Lys Pro Pro Leu Ala Gln Lys Pro Ser Ile Ala Pro Arg Thr
1125 1130 1135
Asp Asn Gln Leu Asp Lys Lys Asp Gly Val Tyr Pro Ala Gln Leu
1140 1145 1150
Val Asn Tyr

(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
GAAGATACCC CACCAAAAC 18

(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
GCTTGACAGT GTAGTCATAA AGGTGGCTGC AGTCC 35

(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
GGACATGTCC AGGGAGTTGA ATAC 24

(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: yes
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
CUACUACUAC UACUAGGCCA CGCGTCGACT AGTACGGII GGGIGGGII G 41

(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 516
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 1 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TCGTGAGAAG GTTTGGAGGG GAGAGAGGGG CAGCTGGAGT GTCTTGAGGC ACGTGTGCCC 60
CTGACCTCTG CTGCTCTTCG TCTCTCGTCC GAGAATAAA GTGCCTCTCC GGGATGAAA 120
GATCTCTTTT GTGGGGGCTT TAAATGCGCT GTGTGTGCTG CAAAGGAGTG AAGGCGGCG 180
GGACCAGAG CTGGGAGCAG CCAATGCGCA GCACTGGGCT GCACTCCCTC AGGAGCGCA 240
GCCAGCTGCG TCTGGGAGC GCTGCCCACC TCTGCCCTCA GCTGGGGGCC TGCAAGGAC 300
GGACCCCGGG TGAGGAGTGGG GAGAGTTGGC TGAGGAGAGA GAAAGGGGGC GCTCTGGAGA 360
GGCTCTCACG CACCTCAGCA GCTTATGCA TCTCATCCCT CTTTCCTCCT CCTTCCTGTT 420
TTTCTAGACT GTGACGATCA ATAGCGCCAT TAATACGACG GAATGGGCTG TAAGGAATAA 480
ACACCGCGAG AACATCCTTTT GGAAGGGCT TGGAAG 516

(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 193
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 2 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

TTTTTTCCAT AACCCCCCCT CACCATGCTC ACTGGGCACC CACCATGAGA AAGGGGCACA 60
GACCTTCTTG CTGCTTTGCT ACGCCTGCC CTCTCTTCTG AACCCAGTGG TCTGCTGGAA 120
GTGCTGGCCAT GTGTGTCGCC AACTCCTCCG AGATGGACAC CCGAACGTTA GTTCTGGGG 180
CTATGGGGTG GCA 193

(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 104
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 3 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GTTTCTTTTT GCCCTCGCAG GTCTTGAGAG ACTCTCGAG ATACGAAAAT GAATGAGTG 60
ACATGAGCAG GATGCGGGTG AGTTGGAGAG TGTACTCAGG AGCC 104

(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 327
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 4 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
AATTCCCTGGG TGCAGATCTC TTTGACTCTTA GTGTGCTGTT GGTGACCTCTG TTTCCCCCTCC 60
TCTTCCTAAA AGGCGCCACCT GAGCGAGGGG TAATGGCCAGC TGTCGGAGACT CTACCTGAAA 120
CTGGCTAGAGA CCAAGATGGA GTACCCACACC AAACGTGAGTC TCTCGGGACA GTTCTGCCCC 180
CACCCCGCGC TCCCTGTCTGC CATCCCTTCA GCCCCTCCTC GAGCTCATTTT GTCAGCCTTT 240
TCAGGTAATTA GACACGGCCAG GTCTTGAGGG AGGTGTGCAC ATCATGTACC CAAGCTGTGA 300
GAGAGGAAAG CCACCGCCAG GCCCAGC 327

(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 331
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 5 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
GGTGGCTCAAGGC AATCCTCCCA CTTGGGCTTAC CCAAGTACCA GGGACCACAG GGGGACACAG 60
CAGCCCGCGG CTGAGAGAGG GCCCTCTCAAG TCTTCTGAGCT TCTCTCTGCC TGACTCCCTC CTCCTGCCCTC 120
CTCCAGAGAA CAGCTCTTGT GCAGATGAGG TGTCGGAGCT CTGGAGAGCA GGGGAGGAGA 180
AAGCTTCTTCT GAAATGTGAC ACTCTCTCTTA AGGTGTACAGG AGGTGTACAGG GGGGAGGAGA 240
CGTGGCTGTGG ATGGGGACCA AGGCCCCCTTG G 300

(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 470
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 6 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
ACGTGCGCCTG TCACTGTGTA CTTCCACCAGG CTGCGATGGC CAATAATACCCA CAAGGCTAAG
ACCTGGGGAGC GCTGTGATGT GTCCTTTGTTGC GCAATGCAAT GAGCATTGGA GACTTGAGTA
GGCTAGAGCC TGGGGGAGGG GACAGGTAAC AGACCCGCGCT CAGGCTGTGG AGTGGTAAAGC
CTCTTTCTCT TCAGCAGGCTG TTTCTAGTTA ACAGTGGAGA TGGTTGACTA CCTGGAGTTG
GAAACTTCAA CTTCCCTAAC AGGAGTGACT CTCTTTCTCC GTCTAAACCACA GGGCTGCTGC
GGAGACTCCT AATCCCTCTTG CCTCCCTCTCC CTGCAAAGTTG TGACGCCAGA GGCTAGGAAG
AATGGGAGAGA TTTCCACCAC ATCTCTGTCT TCTCCCAAACGC TCTGGCAAGG AGGGACTGAA
CCTGTGAGT ATTTTTTTTT TTAAGGACAA AGGTCTCGGC CGGGGTGACG

(2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 565
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) ORIGINAL SOURCE:
(A) ORGANISM: human

(x) FEATURE: exon 7 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
TCTCTACCTG TTTAAATGGGG ATACGTTTAC CTATCTCTATG GGAGTGTGGT GAAGGTAAA
TGAATTTAGT GAGTTAACAG ACGCACAGAA TCCGCTCTTG GTGTATGTTG GACCCCCGTC
TCTGGCCCTC TGAAGAGGCT GCCTGTAACG CCCCCTGCTTT ACCACCCCTT TCCCTAACG
TTATTTCCTA GTATTCAACT CCTGAGCAGT GTCCCGCTCTG GTGTCCGCTGA CGGCAGCAGG
GGGAAGCCGCC CTGCCCCGG CAGTCGGAGG CATCTTTGAGA TGGAGGCACC TTTATGACTA
GATCTTCAAG CTTCTCCTCA AACTCCACTC TGATGTGACT GCAGGAGGGC ATCTTTCTAC
ATGAGATTCA GGCAGAGGCG AGGCTGCCAG CCTGAGGATG TCCCCAGAGA AAGCCAGTCC
TCCCTAGGGCT CTTGCTTGCTG TCCAAAGGCG CCGGGAGCTT CTGGACATTG
TGGAGAATAA AGAGCCAGGG CCAAAGCTTG GTGACCAGCCA TAAAGCCCT CGCTGGCCAC
TCTGGCCCTC AGTGTTTAGG GATCT

(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 233
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) ORIGINAL SOURCE:
(A) ORGANISM: human

(x) FEATURE: exon 8 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
GGGACAGCCTC TAGCAGCCATC GTGCCCCCTG GGAGTGCTGG GCACATGCC CCAGGCTAGCT 60
GGGCCCCCTCC CCCCCAGAGG CCCGCTTTGTC GCTTTCCTCC GTTCTGCCA CCCCCTCCCT 120
TCCACATCTTT TCCAAATTCCT TCCAGGGCCCT ACAGCTAGAC CACCCTGCAAG CGACCGGAGC 180
CGCTTCATGG AGCAATTTAC AAAGTAAGTG GTTCAAGTAA CAGGAATGGA GGT 233

(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 578
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exons 9 and 10 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
TGATCCCAAG CACCATGAGG GATATCTCTTT TGCACAGCTG TGCCTTGGTC CTGAGGAGGGG 60
GGCCAGCAGG CGAGGCTGGTC GCCTGTCGCC CTACATGAGG CTGATGAGAA CACCCAGAC 120
CCCTCAGGTC CTCCCTCAAC CCTAGGTGCA AAGATCTGGT CTAGCTGAGTC AGCAGCTGGA 180
AGCAGACTCA GGGCGTATTT CAGATCCCCC AGCCTGGTGA GGTAAAGCATG CCAAACACAC 240
CACCTGGGGG AGCTCAGGAGG CCCCAGTACT TCTCTTAAGG GCGGGCGGGG CTCGGCAACG 300
AAAGCCTACT TTGGAGATGG TCCTCGCTCT CAGAACCCAC CCACTTCCCA CGGGCGCTCA 360
GCCCTGGCAC AACATATCGG CCGTGCTGCG GTAGCTCCTG CAGAGCCCTC ATCCCCGCCG 420
AGCCAGCCAG TCTAAGGAAG GGAATGACCC CTTGGATCTG ATGGAGACAG AGGGCTGAGG 480
ACCACCTGGG AGAGAATGTT GCCCTTCTCT CTCACCTGTA AGTACAGGGG AGAGGCTGGG 540
GGGAGCCTTG GCCAAAGGCC ATGGACTCTA ACCAGGGT 578

(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 390
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 11 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
AAAAAAAAATTT AAAAAATTTA ACAGGCTCGA ACCGTTTAA TCGAGAAAAG GGGCATCTCC 60
CCCATCCTCT CATCGACAGA ATACAGAGAA TTCTCTGCTCT CTCGACTCTA TTCTCACTCC 120
TTTTTTGCTCA ACCACAGAAT TTATTTGACA ACAAGTTGGA TGGCATCTTTT GGGCGTTGAT 180
TCCAGGCTGA TCCTCCCTCTA TTCAACACTG AAAATGGTGT GAACAAAGAT AGAAGGCTG 240
TCCGAGGGGG GTTACGACAG ATGGTTTGA AGCAGTGTTA AGCCAGCTGC TGCCTCAAAA 300
CACTAAACAA AGAGGAAATTC TTAATGATAC TGGGCTTCTT TAGATACAGA ACATCTTTGA 360
GGGGGGGAGA CAATGGCCTAA TOCCCGTAT 390
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 547
  (B) TYPE: nucleic acid
  (C) STRANDEDNESS: double
  (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
  (A) ORGANISM: human
(x) FEATURE: exon 12 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
  AAAATCAATA ACCATTTGATT TATGATATT AGATTTAGAT ATGTTAACAT TTGATGATA  60
  ATTTAAGGCA TTTCAAAGAA TGTTCCCAAA ATTAATACCA GCTTTTAAAT TCTTCCTCTCT  120
  AGCTCACAATT TAAAAAACAGA GGGTATGAGG CACTATGAAA GCACATGATT CCCCCCTCTC  180
  TCCCGCAAGGA CCACTTAAAAT GACGCGATAT ACAAGAGAGAT AGTGGATTG AAGCAGAGGC  240
  TAGAAACACAT GAGACTGATT GATATACTTG GATCTGCTCCT GCTTTTGAGG TCTCCTAAAA  300
  CACGCTGATT TTAGTTGTTA AATTTGCATT ACACGTCCCA GCACAGTGGG CTACGCCTTTG  360
  TAACTCTCAGC ATCTTGTGAG GACAGAACTAA CGCGGTAACAC TGAGGTCAGG AGTGGACGAC  420
  CACCTGAGGA AACAGGTTGA AACCAGCGTC TCTCAAAAAC ATGGAAATA TACCCGCTGG  480
  TGGTGCCCCG CACCTGTAAT CCCAGCTACT CGGGAAGCTC AGGCAGTACAG ATTCCTTGAA  540
  CTGGGGA  547

(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 436
  (B) TYPE: nucleic acid
  (C) STRANDEDNESS: double
  (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
  (A) ORGANISM: human
(x) FEATURE: exon 13 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
  CCCCCAGCCA CTCTAAAGAG GACCGAATTT CCCCCGCCC CATCCCCCTG TATTGTTGTT  60
  GATGAGGAGC CTCTAAAGGA CCAGATGCTC CAACTCTCCT GGGAGTGGGA GAGTGGACTT  120
  AGGCGAATCA GATTTTACTG TGAAGAATGC GAGTGACCAG CTTCTCGGAG CCATGCCCGT  180
  GACCCGTTCG AGTGGGCCGTT TGGCTCAGTG ACCGAATCAG CCCCCAGGAC CCAGCGGTTT  240
  CTGCTGCAAG CGAAGGCCGCA CGTCAGGGAG CTGGAAGACG ATCTGGCCGA CGACGAGCAC  300
  CTGCGGCGAG CGCGCGCGGA CGACGTGAAAA TCTCTCGGCG CAGAACTGGG CGAGCTCAGG  360
  AGGCAGGGCG AGGCACCGGA GAAGCTCGAG CGGAGCCTGCT CTGAGATAGA AAGTGAGCGG  420
  TGGCTGGCGG CGGGGG  436
WO 99/60986

PCT/US99/11743

(A) LENGTH: 469
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 14 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
GACCTTGAGCC CAAGGAGGTG AAGGGCTGCAG TGAACAGTGTA TTGTGCCACT GCACCCGACG
CTGGGCGTGCA GGAACCGAGCT GCTCTCAGAA AACAAACAGGA GGAACCTTCGTA GGAGCCCTTG
GCTGGCCGCA GGAAGGCGAG GGTCCTGTGT AGGTTAGACT CCTACAGCTTG GTCTCCCTACG
ATACAGGAAA AAGTCCAGAG GTATAGCAGA TCTAAAGGAG GAAAGTACAGG
AGCTGCTGTC GACGCCGCTG GACCTGCTGC GGAGGTGTAAG ACCCTCGACC CCTGCTCACA
CTCCGGCGAGCC CCTGCTGTCAG GCCTGTCAGG CTCGGTCGCG CTTGTTGCGTT CCCCCGGGCC
AGCAACCCCT GACATTGCATCT CTAAGGCAATTC GGGTGAATCT GGGGACCCAC ACGCTTTTGAG
GCTTCCGTTGC CCTCATTGCTT TGGGCGCTGTG CCTGGCGTGCC AATCCCATTG

(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 359
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 15 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
GGGTAGGAAA GGTATCCAGCT TCTCCGATCT TAGGGCGACGC ACAGGGTGAG TATGATTTGCT
CTAGAAAGGAG GATGTCTCTCT AAGGCTGGAG TCTCCGTTGG TAAGACACTG TTTCTATTT
GCAGATGGCA GAGGGACATC CAGCGAGGTCT CAGTGCTCAGA CGACGCCAGG TGGATTGTTGA
ACAGGAGAAA AAGGGCTGGAG AGATTTGGTTA GGAGGCGCATC AGTGACAGGG GCCACGGAAA
GGTGATGGGG AGCGAGAGCA CTCGGGAAAT GAGGGAGGAG GCTGGTGAGGT TGCTGGGCAGG
GGCTGTGTGG CTTCTCTGTCG CATGGGCAAT TCTGTTGCTGG GTGGCGTGATC ACACAGCAG

(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 209
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 16 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GTTGATCGGT TGGGAGGTCT TTACATTTTT ATATTCTTCT GCACCTGACG CCTAGTCAGA 60
GTCCCTCTGG TTCTCTCTCT TTTCACTAGC AAGAACAAGCT GGAATGCTA GAGCCTTGA 120
AGCAGAAGCT TCACCAAAAC GAGGAGGAGC TTCCAGTTTCT GCAAGGCAGC CTGGAAACTT 180
CTGCCAGGTT AATACTCTCC TTTTTTTTT 209

(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 485
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 17 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CCCCCCTGSC AATCATGTTG TCCCCGGGAG GGAATCAGAG TGCCAGTTTA AAGAGGCCAC 60
ACCTCCCGAG CTTAGTCAAC CGGCTGTTGG GGGGAGGCTG GGAGCTGTTPA GGAAGGCTAG 120
ACTCAACCGAG CTCTTCCTTC TTTCTCTTTG GTCACTCTTG CAGTCAGAGG CAAACTGGGC 180
AGCCAGTGGC GCGGAGCTAG AGAAGGAGGG GACACAGGCTG TGAGTGCTGGG CACGCTCATG 240
GGAGAAGGAA TTATCTGCTC TGGGAAGAAG ACTGCAAGGG AACTGAGCTCA AACTGAGGCA 300
CAGCAGGAGT CAGGAGGAGG CACAGGAGGG AGGAACCTGGG AATCCGAGCC GAGGGCGCTA 360
GCCCATACGC GAGAAGGCTGG AGGACCGCGG GGGCGGTGAG AAGGGTCTGG GGGCGTGTCG 420
CTGATGGTGAG AGAACATTCTG TAGGCTGAAT GCCAGAGCC CCGTGTTGCTGC CTGGCGAGGT 480
CATTGA 485

(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 468
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 18 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

TTACTGGCCT GTGCCCGCTTT GCAGCTGACT TGAGCTTAGAG TGTTAGAGGC CCCAGCCAGG 60
TCATCCTGCT CAGGTTTCTT ATGAGTCTTA GGCGAGACCT TCACCTCTGT GGCCCATTTT 120
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 393
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: double
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
   (x) FEATURE: exon 19 of HIP1
   (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
      CACTAGTAAG CTCTTCCATT CAGGCTTCTTA TTAAGCAGGA TGAAGCCAGC TATGAGAAGT  
      TGCCTCGACC TGCCCTCTTG TCCCTCCTCA CAGATCACCT CCTCTCCAGG GTFACATCTCA  
      TTTCCACGCTG CATGGAGCCA CTTGAAGAAA GCTGGAGCCA GTATCTGGCC TGGCCAGAG  
      GTAAGATGCG CCAAGACAGCG TCTCTGGCG CTATGTGATGG CCAGACAGGG TCTCAGAGCA  
      CCTGAAATGG GGAGATGTGA CAGGTCCTCT TCATCAAGGA AAGCCATGTA GGCAACTCAT  
      ACAAGAAGG CATGTAGGCG ACACTCATAAA CGGGAGGAGA GGGTATGAAA GGTTCACCAG  
      CAAACAGACC TGAGAAACTT CTCTTTCCAA TCC  

(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 421
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: double
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
   (x) FEATURE: exon 20 of HIP1
   (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
      GGCGCTGCCCA GAAAGTAAAG GTGGCCAGAC ACGACTCTGT GCGGTATGG TGAGCCCGAGCC  
      AGGGTTCAAG AAGCACTGGA TGGCGGGTAA GTGACAGGTC CTCCTGCACT AAGAAAGGCA  
      TTAGGCAAC CATCAACAGA AGGGCATGTA GGCACACTCAT AAGACGGGAG GAGGAGGATAT  
      GAAAGTCTCA CGATCAACCA GACCTTGAAG AACTCTCTTT CCAATCTGCG CAGACATCGA  
      TGGGCTCCTC CATCTCATAA CCCGGCCTGC CCACTTGACC AGGCAAGCCA TGGGCTCATGC  
      TGGGACCCAG GCCTCGAGCA GAGGCAGGCCC ATCTTGATGG GGCGCGCCGA GGGCTTCTCA  
      TGGGCTTCAG GACCGAGGGC CTCCTCGTTG TCTCTGATGG GGGCGCCGCA G  

59
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 498
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: double
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
   (x) FEATURE: exon 21 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
AGGCCGGAGC AGGAGAATCG CTFGAACCATG CAGGCCGGAG TTTGCAGTG CAGGAGATGG 60
CGCCACACCA CTTCCGCGCTG GCAGCAAGGA GCGAGCTGCG ATCTCAAAAA AAAAGTGCTT 120
ATGGCCCTGT ATTCGCCAGCA TGAACCTAAG GCTGCTAGGCA GTATGGGAGG GAAACCTCG 180
CCATCCCCGGCT TTTCTTGCGAG GAAAGGGGAA GCCCTGGAGAA TGGCGACAGC ACCAGCATGA 240
GGACATTGCT GCAGGAGATCC AGGCCCAATCG GCCGAGTACT TGGAGTATGA TATATTGAGGA 300
GCATGTTAT TTAGTGTGCGG TGCTGTGCGTG GTGAAATGACG AGGAAATCTG TGTAGTTTCTG 360
AGCTGACTCT TCTGGAACCT TCAAGCTAG TCTGAAAGA GATGGTTAAA ATGGAAATAT 420
CTGGCAGGGG GTGGGATGTTT ATGCGTGATA TCCCGGACTC TGTGAGGGG CAGTCAGGAG 480
GACACTT GGAACAC 498

(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 427
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: double
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
   (A) ORGANISM: human
   (x) FEATURE: exon 22 of HIP1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:
CCCTTGGGAC TGGAGAGATT CTTTGGCTGG TGGCCCTTCTC CTTTGGCATACT TTTGTAAGGTT 60
TACAGATGCC AGAGAGAGAC CAGACAGAAG GGGCGATGCG ATCTGACCGC TTCTGATTGT 120
TTACAGGAGCG CTCTGCGCAA GGGGCACCTG GAATAGAGAC GAGGATGAGCG GGGGCATTG 180
GGACAGGAGG ATGCGGGGCA CTCTCGCTGC TATTTGAAAC TCCACGCGAC GCACGGCGCG 240
AGGAGGTTCC TCGAGGATCT CGTGAAAGCA TGGTGTTTCC CACTGACACTG TGGCGGACCTG 300
CTCATTAAGCAT GTGCGAGATT GCTCTAATAA GCACGGGCAA ACCCGTGAGA ACAGAACA 360
GAATTTGGCA GGGACAGTTG CTCATGCCCCT TAACCCCGAG ACTTTGGGAG GACACTTTGA 420
GTCCAGG 427

(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 367
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 23 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

CCGCCGACAA TGGTTGACGAA ACCTCAGGAC CCTTTTCTAC TGGTTGACGAA TGGTTGACGAA 60
CTTGGGGACT TCGTGTGTCG GATTTCCAG AACTGTGAC ACGTGTGAC ACGTGTGAC 120
TAAGGACTTTA GTGATGCTTAA AATATCTAAG GCACCTTATG AAACTATGTC TCTTACTTAC 180
AGGAGAGCTC ACACAACTCC CGAGCAGGAG ACGACGGGAT CAAATTGGAG GTGAATGAAA 240
GGGCGTCTCG AAGTCAGCGG TGGGAAGCAGTG GCACCTTACCC TGGACATGCT 300
CGAAGGTCTTG AAATGCATTT TGGAAATTTG AAGAAGCGCA TACGCAGCCG 360
TGAGGTTG

(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 502
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 24 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

CCGCCGACAA TGTTGAGCAGG AACTCAGGAC ACCATTTTAC TGGTGTGTGC TGGTGTGTGC 60
TGGTGTGTGC AAGAAGCGCA TACGCAGCCG 300
CAGGCTCTCC ATCAGGACAGGAGAC CCTTTTCTAC TGGTTGACGAA TGGTTGACGAA 120
TAAGGACTTTA GTGATGCTTAA AATATCTAAG GCACCTTATG AAACTATGTC TCTTACTTAC 180
AGGAGAGCTC ACACAACTCC CGAGCAGGAG ACGACGGGAT CAAATTGGAG GTGAATGAAA 240
GGGCGTCTCG AAGTCAGCGG TGGGAAGCAGTG GCACCTTACCC TGGACATGCT 300
CGAAGGTCTTG AAATGCATTT TGGAAATTTG AAGAAGCGCA TACGCAGCCG 360
TGAGGTTG

(2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 437
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 25 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:
TTTTGTCCTC TCAGATTCTT CTCTTTTTGTT AAAATGGGAA TACTATGCT TATGCTCAG  60
AGTTTCTATG AGAGAGATTT GGTTAATAT ATGTAATAAA GCAGCTGCA AATGATACAT  120
GCTGCTATAA AGAGCTGCTAT TACATTTTTT TACTTTTCCA GGCTACAGCA TCCCCTAAAG  180
AGTTTATGCC CAGAACTCCT CGTGGAGCAG AAGAACATAT CTCAAGCCCTT AAGGCTTTGG  240
GCTGGGGGAGC AAGCTGCTATG GTGTAAGTAT TTATGTGTAC CAGGGTGCTT CCCATTGACC  300
CTTCTCCATG GCACGCCCTT AAACAAATAG TAAGGGAGGA AAAAAAATTC TGCCCTTTAG  360
AAATAAAACTT TGGATCAGGA AGTCAAATGG ACCGAGTTPA CAGGGAGGCC TTGGCTCTCCC  420
AGGGAGCACCA GGGCAGG  437

(2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 351
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 26 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:
GGAGGCCTGG CTCCTCCAGG GGGCAGAGGG CAGGCGACCT CCCCTCCCTG TTTAGGCAAG  60
GCCGAGGGG TGCTCTGAGG GTGGGATGTT GGAGAGGTG TAGCTCTATT GCAGCGTAAA  120
TACGCGCTCT TCGCTGTTTTT CATCAGGGAT GCACTGATGC TGGTGTGATAA AGGGAGCGG  180
AAATTGGAGG AGCTAATGATG GTGTTCTCAT GAATTTGCTG TAGGACACGC CCCAGCTGTTG  240
GCTGCACCCCA AGTGAAGGAC TGCGTCGGACC TCTCTAGGAC CGTGAAAGGCC TGTTTAGGAGA  300
GTAATGGCCT AGTAAAGAGA GTACTTGGCT CGCGTGAAGCA GTACTTGGCT G  351

(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 418
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 27 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
CTTTTTATAT CATAGATATG TCAGAGGCTG ACTATAAGCTA GCAGATTITG AGAAAGCTGAT  60
TGTTGACTGCG CTGTGGGCCC ACAATATTTT GCCAGAAACC ATCAGAGCAA TTATCTGATT  120
CAGTCCCTGTT TGCTCTAGGT GTTTATGAA CCTAAATCTG CTCTTGCTCTG GTAGGTGAAA  180
WO 99/60986

(2) INFORMATION FOR SEQ ID NO:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 279
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 28 of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:
TTTCCACAGA GCATTGGCAT TGGCTGTCTC TCAGGCTGCCA GTCAGCCAGGG GTAGAATTTG 60
ATGAGACCTTT CTAGTTTCCA TCTCTGGACA CAACTAGGAC TCTCAGGTAG AAAAAAGATT 120
ACAGATCCAAA CGGCAAAGAGA TGGATTCGCA GGTATTGAGT CTAAGACCTG AAAAAAGATT 180
GCAGAGAGAG GCGTCAAAGAC TGGGAGAGCT TGGAAAAAG ACTAGACGAC TTTGCGCTGT 240
TGGATGGGCC TGGGAAGAG AAGACTGTGAC TCAAAGGAG 279

(2) INFORMATION FOR SEQ ID NO:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3715
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(A) ORGANISM: human
(x) FEATURE: exon 29 and partial cds of HIP1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:
AACATAAATT ACTATGCTCT TTTAGGAACA GAGGCATCTC CACCTACACT GCCAGAATGT 60
GTACCGAAA AGAAATGAGC CCAAAACAC ACGCCATAAT CGAGTGTCAA TCTTTGTTAC 120
CTATCTGGTG TGTGTTTATT CCCCCACCAG AGGCGAACAT CTTGAGTCTC CAGGGGACGC 180
CACCACCTG GCTATTACCAG TGCTGGAGAG CATGACAGAC ACTTTAAAAA GACTCCCTCC 240
ATAGGAGCAC CTTCTCTGTT TGAGCCATTG GCAGTCTATT TCTGTTTTCC GCCTCCCTAG 300
TTAGCGATTC GGCAGTCGAG TCTGCACGAT GAGCACGCTT AGCTACAGAG AGGGGTGGTG 360
GGGGGAGCGG CACACTCAACA GAGGAGACCA CATCCACAGTC CTGACTGCTA TTTGACCCCA 420
ACACAAATGG GTAATCCATA TAGAGGAGCT GCTGTTGTTT TGGTACAGCC TGGAGAAGGG 480
AAGATCTTAT GCCCTTTTTT TCTCTGTTTT TCTCAGCTCT TCTGATTACA ATCTATGAGC 540
CAACACTTGTG AGCATCAGG GGCATGAGGA TCTCAACACCA GGACATACACCT TCAGATGCTG 600
CACAGTGCA GAGACAGCAG GAGTTCTGCTG GCTGTAAGTC CAAAGCGACT TCTCACCCTG 660
TTGCGGGGACT GCATTGAGAT TCCACTGCCT CTTATGGAGG TTTGTTTGCTG TTTTTTGTTT 720
TGGGTTTTTT TTTTAATTTT CACTCAGATA GCCAACCTCC CAAAGGGGCA CACCGCTGAG 780
GCTGAGTCCT CAGGCCCCCG CAACCTGTGGT GATCTGACCAG ATGGTGCCGCT CAGAGCCCTC 840
<table>
<thead>
<tr>
<th>Application No.</th>
<th>International Search Report Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGTGCTCCA</td>
<td>TCTCGCCCTCA CAACAGTACGG AAGTGCTGGC CACCACAGTC CATGCTCCAG</td>
</tr>
<tr>
<td>GCTCAAGGCGG</td>
<td>AGCTGCTAGAG TACAGCTTTT CTCAAAAAAG CAGAGGAAGA GTGAGTGCTC</td>
</tr>
<tr>
<td>TTCTGCACTTA</td>
<td>AACCTGGAAAA GCCCTGCTTCC GCTTTCAACA GGGAGAGAAG 1020</td>
</tr>
<tr>
<td>AACAGAGGAAA</td>
<td>GCCGCCCCAG GGCGAGGGG GTTGGCTTCC CACAGGTTCC CTTCAAAACT</td>
</tr>
<tr>
<td>TACACATATG</td>
<td>TCTGAGGAGA TCTGCGTCTG CAGACCAACT TACATCCCTCA GCTTCCAG</td>
</tr>
<tr>
<td>CTGTCCAGTTA</td>
<td>CGCTCAGTTT CATGAGGGG GCTGCTCAGA GGAGCAAGAG 1200</td>
</tr>
<tr>
<td>CATGTACATG</td>
<td>ATGCTGCTTT CAACGTACCT TGGGATGCTCT TGGGGAGGAA GCTTCCAG</td>
</tr>
<tr>
<td>ACAGCTGATC</td>
<td>AAGAGAGGAA TCTACCTTTG CAGGGGTGGT TTGCTGGTTTTT 1440</td>
</tr>
<tr>
<td>GGATGGTAAG</td>
<td>CACAGTCTAA AAGATGCTTG TATGAGGGCTT GATTATGGTTT 1500</td>
</tr>
<tr>
<td>TTCTGCGGCA</td>
<td>GCGGAGCTAG AGCTGGCAAG CAGAGGCGAG 1620</td>
</tr>
<tr>
<td>CAGCACTCATC</td>
<td>CTGGGCAACA TGCAGGGCTT GGGACCAAGA CAGGCAGGAT</td>
</tr>
<tr>
<td>ACACATCTTGT</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>GGAGCTCGCTT</td>
<td>ACAGGGCAGG AACAGGGGGG TCTGCTACAG GCAGACAGGA</td>
</tr>
<tr>
<td>TTCTGCTATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 2100</td>
</tr>
<tr>
<td>CAGAGAGGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2160</td>
</tr>
<tr>
<td>ATGACTCTGA</td>
<td>GTTGTCCAGC TGCAGAGGGA TACAGGAGG TGGGTACAGG 2220</td>
</tr>
<tr>
<td>GTGGCCGAGC</td>
<td>ATGGTTACAG TGGGTACAGG TGGGTACAGG TGGGTACAGG 2280</td>
</tr>
<tr>
<td>ATGACGTTGAGG</td>
<td>GGAGGAGGAG AATTAGAGTT AAGATGCTGT TGGGTACAGG 2340</td>
</tr>
<tr>
<td>AACAGCTGATC</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>TTCTGCTATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 2400</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2460</td>
</tr>
<tr>
<td>GACAGCTGATC</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>TCCAAGGAGG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2520</td>
</tr>
<tr>
<td>ACTTGCCGAGG</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2580</td>
</tr>
<tr>
<td>CAGGAGGAGG</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2640</td>
</tr>
<tr>
<td>CAGGAGGAGG</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2700</td>
</tr>
<tr>
<td>CAGGAGGAGG</td>
<td>ATGAGAGGAA GAGGAGGAAA CACAGGACTG CACAGGGGTC</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2760</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2820</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 2880</td>
</tr>
<tr>
<td>AAAAGAAAAA</td>
<td>TTACCAAATG TATAGGATCA CAGAGGAGG GAGGAGGAGG</td>
</tr>
<tr>
<td>CATGCTGATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 3180</td>
</tr>
<tr>
<td>CATGCTGATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 3140</td>
</tr>
<tr>
<td>AGATGCTGATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 3240</td>
</tr>
<tr>
<td>TGGGAGGAGG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3300</td>
</tr>
<tr>
<td>AGATGCTGATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 3360</td>
</tr>
<tr>
<td>GAGTGAAGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3420</td>
</tr>
<tr>
<td>ACAGAGGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3480</td>
</tr>
<tr>
<td>TGAGGAGGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3540</td>
</tr>
<tr>
<td>TGGGAGGAGG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3600</td>
</tr>
<tr>
<td>GCAGGAGGAG</td>
<td>AATTAGAGTT AAGATGCTGT TGGGTACAGG TGGGTACAGG 3660</td>
</tr>
<tr>
<td>CATGCTGATG</td>
<td>CACAGGAGG TACAGGAGG CAGGAGGAGG 3715</td>
</tr>
</tbody>
</table>